<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">37202</article-id><article-id pub-id-type="doi">10.7554/eLife.37202</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title><italic>tp53</italic> deficiency causes a wide tumor spectrum and increases embryonal rhabdomyosarcoma metastasis in zebrafish</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-110173"><name><surname>Ignatius</surname><given-names>Myron S</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/><xref ref-type="other" rid="dataset1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-61925"><name><surname>Hayes</surname><given-names>Madeline N</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund8"/><xref ref-type="other" rid="fund9"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/><xref ref-type="other" rid="dataset1"/></contrib><contrib contrib-type="author" id="author-110174"><name><surname>Moore</surname><given-names>Finola E</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-110175"><name><surname>Tang</surname><given-names>Qin</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-9487-570X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-110176"><name><surname>Garcia</surname><given-names>Sara P</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund8"/><xref ref-type="other" rid="fund9"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-110177"><name><surname>Blackburn</surname><given-names>Patrick R</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-0658-1275</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund10"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-110178"><name><surname>Baxi</surname><given-names>Kunal</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-110179"><name><surname>Wang</surname><given-names>Long</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-110180"><name><surname>Jin</surname><given-names>Alexander</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund8"/><xref ref-type="other" rid="fund9"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-110181"><name><surname>Ramakrishnan</surname><given-names>Ashwin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-110182"><name><surname>Reeder</surname><given-names>Sophia</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-30616"><name><surname>Chen</surname><given-names>Yidong</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-61930"><name><surname>Nielsen</surname><given-names>Gunnlaugur Petur</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-110183"><name><surname>Chen</surname><given-names>Eleanor Y</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-110184"><name><surname>Hasserjian</surname><given-names>Robert P</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-102016"><name><surname>Tirode</surname><given-names>Franck</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-4731-7817</contrib-id><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-110185"><name><surname>Ekker</surname><given-names>Stephen C</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-0726-4212</contrib-id><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="other" rid="fund11"/><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-61240"><name><surname>Langenau</surname><given-names>David M</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-6664-8318</contrib-id><email>dlangenau@mgh.harvard.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund8"/><xref ref-type="other" rid="fund9"/><xref ref-type="other" rid="fund12"/><xref ref-type="other" rid="fund13"/><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf1"/><xref ref-type="other" rid="dataset1"/></contrib><aff id="aff1"><label>1</label><institution content-type="dept">Department of Pathology</institution><institution>Massachusetts General Hospital Research Institute</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>Massachusetts</country></aff><aff id="aff2"><label>2</label><institution content-type="dept">Center of Cancer Research</institution><institution>Massachusetts General Hospital Cancer Center</institution><addr-line><named-content content-type="city">Charlestown</named-content></addr-line><country>Massachusetts</country></aff><aff id="aff3"><label>3</label><institution>Harvard Stem Cell Institute</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>Massachusetts</country></aff><aff id="aff4"><label>4</label><institution content-type="dept">Department of Molecular Medicine</institution><institution>Greehey Children’s Cancer Research Institute</institution><addr-line><named-content content-type="city">San Antonio</named-content></addr-line><country>Texas</country></aff><aff id="aff5"><label>5</label><institution content-type="dept">Department of Laboratory Medicine and Pathology</institution><institution>Mayo Clinic</institution><addr-line><named-content content-type="city">Rochester</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution content-type="dept">Department of Pathology</institution><institution>University of Washington</institution><addr-line><named-content content-type="city">Seattle</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution content-type="dept">Department of Translational Research and Innovation</institution><institution>Université Claude Bernard Lyon, Cancer Research Center of Lyon</institution><addr-line><named-content content-type="city">Lyon</named-content></addr-line><country>France</country></aff><aff id="aff8"><label>8</label><institution content-type="dept">Department of Biochemistry and Molecular Biology</institution><institution>Mayo Clinic</institution><addr-line><named-content content-type="city">Rochester</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="senior_editor"><name><surname>Bronner</surname><given-names>Marianne E</given-names></name><role>Senior Editor</role><aff><institution>California Institute of Technology</institution><country>United States</country></aff></contrib><contrib contrib-type="editor"><name><surname>White</surname><given-names>Richard M</given-names></name><role>Reviewing Editor</role><aff><institution>Memorial Sloan Kettering Cancer Center</institution><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>07</day><month>09</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>7</volume><elocation-id>e37202</elocation-id><history><date date-type="received" iso-8601-date="2018-04-02"><day>02</day><month>04</month><year>2018</year></date><date date-type="accepted" iso-8601-date="2018-08-22"><day>22</day><month>08</month><year>2018</year></date></history><permissions><copyright-statement>© 2018, Ignatius et al</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Ignatius et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-37202-v1.pdf"/><abstract><object-id pub-id-type="doi">10.7554/eLife.37202.001</object-id><p>The <italic>TP53</italic> tumor-suppressor gene is mutated in &gt;50% of human tumors and Li-Fraumeni patients with germ line inactivation are predisposed to developing cancer. Here, we generated <italic>tp53</italic> deleted zebrafish that spontaneously develop malignant peripheral nerve-sheath tumors, angiosarcomas, germ cell tumors, and an aggressive Natural Killer cell-like leukemia for which no animal model has been developed. Because the tp53 deletion was generated in syngeneic zebrafish, engraftment of fluorescent-labeled tumors could be dynamically visualized over time. Importantly, engrafted tumors shared gene expression signatures with predicted cells of origin in human tissue. Finally, we showed that <italic>tp5</italic>3<italic><sup>del/del</sup></italic> enhanced invasion and metastasis in <italic>kRAS<sup>G12D</sup></italic>-induced embryonal rhabdomyosarcoma (ERMS), but did not alter the overall frequency of cancer stem cells, suggesting novel pro-metastatic roles for TP53 loss-of-function in human muscle tumors. In summary, we have developed a Li-Fraumeni zebrafish model that is amenable to large-scale transplantation and direct visualization of tumor growth in live animals.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>angiosarcoma</kwd><kwd>germ cell tumor</kwd><kwd>MPNST</kwd><kwd>leukemia</kwd><kwd>rhabdomyosarcoma</kwd><kwd>metastasis</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Zebrafish</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>R24OD016761</award-id><principal-award-recipient><name><surname>Ignatius</surname><given-names>Myron S</given-names></name><name><surname>Hayes</surname><given-names>Madeline N</given-names></name><name><surname>Moore</surname><given-names>Finola E</given-names></name><name><surname>Tang</surname><given-names>Qin</given-names></name><name><surname>Garcia</surname><given-names>Sara P</given-names></name><name><surname>Jin</surname><given-names>Alexander</given-names></name><name><surname>Ramakrishnan</surname><given-names>Ashwin</given-names></name><name><surname>Reeder</surname><given-names>Sophia</given-names></name><name><surname>Nielsen</surname><given-names>Gunnlaugur Petur</given-names></name><name><surname>Chen</surname><given-names>Eleanor Y</given-names></name><name><surname>Hasserjian</surname><given-names>Robert P</given-names></name><name><surname>Langenau</surname><given-names>David M</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100001445</institution-id><institution>Alex's Lemonade Stand Foundation for Childhood Cancer</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Ignatius</surname><given-names>Myron S</given-names></name><name><surname>Hayes</surname><given-names>Madeline N</given-names></name><name><surname>Langenau</surname><given-names>David M</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>R00CA175184</award-id><principal-award-recipient><name><surname>Ignatius</surname><given-names>Myron S</given-names></name><name><surname>Baxi</surname><given-names>Kunal</given-names></name><name><surname>Wang</surname><given-names>Long</given-names></name><name><surname>Chen</surname><given-names>Yidong</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003645</institution-id><institution>National Cancer Center</institution></institution-wrap></funding-source><award-id>RR160062</award-id><principal-award-recipient><name><surname>Ignatius</surname><given-names>Myron S</given-names></name><name><surname>Baxi</surname><given-names>Kunal</given-names></name><name><surname>Wang</surname><given-names>Long</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>R01CA154923</award-id><principal-award-recipient><name><surname>Ignatius</surname><given-names>Myron S</given-names></name><name><surname>Hayes</surname><given-names>Madeline N</given-names></name><name><surname>Moore</surname><given-names>Finola E</given-names></name><name><surname>Tang</surname><given-names>Qin</given-names></name><name><surname>Garcia</surname><given-names>Sara P</given-names></name><name><surname>Jin</surname><given-names>Alexander</given-names></name><name><surname>Ramakrishnan</surname><given-names>Ashwin</given-names></name><name><surname>Reeder</surname><given-names>Sophia</given-names></name><name><surname>Nielsen</surname><given-names>Gunnlaugur Petur</given-names></name><name><surname>Chen</surname><given-names>Eleanor Y</given-names></name><name><surname>Hasserjian</surname><given-names>Robert P</given-names></name><name><surname>Langenau</surname><given-names>David M</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>U54CA168512</award-id><principal-award-recipient><name><surname>Ignatius</surname><given-names>Myron S</given-names></name><name><surname>Hayes</surname><given-names>Madeline N</given-names></name><name><surname>Moore</surname><given-names>Finola E</given-names></name><name><surname>Tang</surname><given-names>Qin</given-names></name><name><surname>Garcia</surname><given-names>Sara P</given-names></name><name><surname>Jin</surname><given-names>Alexander</given-names></name><name><surname>Ramakrishnan</surname><given-names>Ashwin</given-names></name><name><surname>Reeder</surname><given-names>Sophia</given-names></name><name><surname>Nielsen</surname><given-names>Gunnlaugur Petur</given-names></name><name><surname>Chen</surname><given-names>Eleanor Y</given-names></name><name><surname>Hasserjian</surname><given-names>Robert P</given-names></name><name><surname>Langenau</surname><given-names>David M</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100003287</institution-id><institution>Rally Foundation</institution></institution-wrap></funding-source><award-id>Amanda Riley Foundation Research Fellowship</award-id><principal-award-recipient><name><surname>Hayes</surname><given-names>Madeline N</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003645</institution-id><institution>National Cancer Center</institution></institution-wrap></funding-source><award-id>R01CA211734</award-id><principal-award-recipient><name><surname>Hayes</surname><given-names>Madeline N</given-names></name><name><surname>Garcia</surname><given-names>Sara P</given-names></name><name><surname>Jin</surname><given-names>Alexander</given-names></name><name><surname>Langenau</surname><given-names>David M</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003645</institution-id><institution>National Cancer Center</institution></institution-wrap></funding-source><award-id>R01CA215118</award-id><principal-award-recipient><name><surname>Hayes</surname><given-names>Madeline N</given-names></name><name><surname>Garcia</surname><given-names>Sara P</given-names></name><name><surname>Jin</surname><given-names>Alexander</given-names></name><name><surname>Langenau</surname><given-names>David M</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>UL1RR024150</award-id><principal-award-recipient><name><surname>Blackburn</surname><given-names>Patrick R</given-names></name></principal-award-recipient></award-group><award-group id="fund11"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>GM63904</award-id><principal-award-recipient><name><surname>Ekker</surname><given-names>Stephen C</given-names></name></principal-award-recipient></award-group><award-group id="fund12"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100006058</institution-id><institution>St. Baldrick's Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Langenau</surname><given-names>David M</given-names></name></principal-award-recipient></award-group><award-group id="fund13"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100005294</institution-id><institution>Massachusetts General Hospital</institution></institution-wrap></funding-source><award-id>Research Scholars Program</award-id><principal-award-recipient><name><surname>Langenau</surname><given-names>David M</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Syngeneic tp53-null zebrafish develop a wide range of tumors that engraft into recipient animals with loss of Tp53 leading to increased metastasis in embryonal rhabdomyosarcoma (ERMS), likely accounting for increased aggression in TP53-inactivated human ERMS.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>TP53 is a tumor suppressor protein that is mutated or functionally disrupted in more than 50% of all human tumors (<xref ref-type="bibr" rid="bib14">Kastenhuber and Lowe, 2017</xref>; <xref ref-type="bibr" rid="bib31">Muller and Vousden, 2014</xref>). Moreover, genetic mutation of <italic>TP53</italic> in Li-Fraumeni patients leads to cancer predisposition early in life and is associated with transformation in a broad range of target tissues (<xref ref-type="bibr" rid="bib26">Malkin, 2011</xref>). <italic>TP53</italic> is commonly inactivated by single amino acid mutations that create dominant-negative forms of the protein that inhibit efficient tetramer formation and block transcriptional activity (<xref ref-type="bibr" rid="bib31">Muller and Vousden, 2014</xref>). In this setting, <italic>TP53</italic> alleles likely alter transcriptional activity of TP53 and its related transcription factor family members, TP63 and TP73 (<xref ref-type="bibr" rid="bib17">Lang et al., 2004</xref>; <xref ref-type="bibr" rid="bib34">Olive et al., 2004</xref>). By contrast, <italic>TP53</italic> deletion is expected to have less wide-ranging transcriptional effects that are confined to tetrameric transcription factor function. Regardless of the genetic alteration, TP53 transcriptional inactivation can lead to genomic instability and impaired apoptotic responses that often are predisposing to a wide array of cancers (<xref ref-type="bibr" rid="bib14">Kastenhuber and Lowe, 2017</xref>; <xref ref-type="bibr" rid="bib31">Muller and Vousden, 2014</xref>).</p><p>To date, several murine genetic models have been developed to assess the effects of both loss- and gain-of-function <italic>Tp53</italic> mutations in cancer (<xref ref-type="bibr" rid="bib8">Donehower et al., 1992</xref>; <xref ref-type="bibr" rid="bib9">Harvey et al., 1993</xref>; <xref ref-type="bibr" rid="bib13">Jacks et al., 1994</xref>; <xref ref-type="bibr" rid="bib17">Lang et al., 2004</xref>; <xref ref-type="bibr" rid="bib20">Lavigueur et al., 1989</xref>; <xref ref-type="bibr" rid="bib21">Lee et al., 1994</xref>; <xref ref-type="bibr" rid="bib34">Olive et al., 2004</xref>). Both <italic>Tp5</italic>3 mutant and null alleles spontaneously develop cancer. However, similar to human Li-Fraumeni patients, the spectrum varies among different alleles, suggesting that the mode of <italic>Tp53</italic> inactivation has important implications in regulating the types of cancer that develop, the time to onset, and the overall propensity for tumor progression (<xref ref-type="bibr" rid="bib20">Lavigueur et al., 1989</xref>; <xref ref-type="bibr" rid="bib21">Lee et al., 1994</xref>). For example, mice heterozygous for the 172His point mutation are predisposed to developing osteosarcoma while animals harboring the 270His mutation develop hemangiosarcoma and carcinoma (<xref ref-type="bibr" rid="bib34">Olive et al., 2004</xref>). By contrast, mice with homozygous <italic>Tp53</italic> deletion mainly develop lymphoma, with rare cases of angiosarcoma, undifferentiated sarcoma, osteosarcoma, rhabdomyosarcoma, testicular tumors, nervous system tumors, teratoma, and mammary carcinoma being reported (<xref ref-type="bibr" rid="bib8">Donehower et al., 1992</xref>; <xref ref-type="bibr" rid="bib9">Harvey et al., 1993</xref>; <xref ref-type="bibr" rid="bib13">Jacks et al., 1994</xref>). Together, these data suggest that differences in gain- and loss-of-function alleles have profound effects on tumor onset and spectrum in genetically engineered mice and yet, largely recapitulate the wide array of cancers observed in Li-Fraumeni patients. Importantly, a small subset of Li-Fraumeni syndrome patients harbor genomic deletions in the <italic>TP53</italic> locus and cancers that develop in dominant-negative, heterozygous point-mutation carriers often display deletion of the second <italic>TP53</italic> allele (<xref ref-type="bibr" rid="bib26">Malkin, 2011</xref>). Thus, modeling complete TP53 loss-of-function in different animal models will likely provide novel insights into human disease.</p><p><italic>TP53</italic> is also commonly mutated in human sarcomas and is predictive of poor outcome (<xref ref-type="bibr" rid="bib45">Taubert et al., 1996</xref>). For example, the <italic>TP53</italic> locus is mutated in 16% of human embryonal rhabdomyosarcoma (ERMS), a common pediatric cancer of muscle and transcriptional activity is altered in &gt;30% of human ERMS through <italic>TP53</italic> locus disruption or MDM2 amplification (<xref ref-type="bibr" rid="bib46">Taylor et al., 2000</xref>). Interestingly, <italic>TP53</italic> mutations are also acquired at ERMS relapse (<xref ref-type="bibr" rid="bib4">Chen et al., 2013</xref>), suggesting a likely role for TP53 in ERMS progression and therapy resistance. Finally, Li-Fraumeni patients with germline <italic>TP53</italic> mutations commonly develop ERMS (<xref ref-type="bibr" rid="bib26">Malkin, 2011</xref>), suggesting important roles for TP53 loss in the genesis of this disease. Yet, to date, the effect of TP53 pathway inactivation on cancer stem cell number, tumor progression, and metastasis in ERMS is not fully understood. Moreover, because genetically engineered mouse and human xenograft models of ERMS do not metastasize in vivo, assessing TP53 loss-of-function in the context of rhabdomyosarcoma metastasis has not been possible. Finally, to date, no <italic>tp53</italic> deletion models have been generated in syngeneic zebrafish, precluding large-scale transplantation studies to assess how deletion regulates cancer stem cells and tumor invasion in vivo for a wide array of cancers.</p><p>To better study <italic>tp53</italic> biology in vivo, we generated a complete loss-of-function <italic>tp53</italic> deletion allele in syngeneic CG1-strain zebrafish using TALEN endonucleases. <italic>tp53<sup>del/del</sup></italic> animals spontaneously developed a wide range of tumors including malignant peripheral nerve-sheath tumors (MPNSTs), angiosarcomas, germ cell tumors, and an aggressive natural killer cell-like leukemia not previously described in any animal model. This model contrasts with currently available point-mutation alleles for zebrafish <italic>tp53</italic> that predominantly develop MPNSTs (<xref ref-type="bibr" rid="bib2">Berghmans et al., 2005</xref>). Moreover, because the <italic>tp53<sup>del/del</sup></italic> mutant was generated in CG1-strain syngeneic zebrafish (<xref ref-type="bibr" rid="bib28">Mizgireuv and Revskoy, 2006</xref>), tumors efficiently transplanted into recipient fish enabling expansion of unlabeled and GFP-labeled tumors, dynamic live animal imaging of metastatic progression, and analysis of transcriptional differences between tumors using RNA sequencing approaches. Roles for <italic>tp53</italic> were also assessed in <italic>kRAS<sup>G12D</sup></italic>-induced ERMS using large-scale cell transplantation assays and live fluorescent imaging over time. Using these approaches, we showed that the overall frequency of ERMS self-renewing cancer stem cells was unaffected by loss of <italic>tp53</italic>. In contrast, <italic>tp53<sup>del/del</sup></italic> ERMS were more invasive, providing a potential explanation for increased aggression associated with TP53 disruption in human ERMS (<xref ref-type="bibr" rid="bib36">Seki et al., 2015</xref>). Taken together, our work has uncovered novel roles for Tp53 loss in the onset of a wide array of cancers and has provided new insights into how <italic>tp53</italic> affects ERMS progression in vivo.</p></sec><sec id="s2" sec-type="results|discussion"><title>Results and discussion</title><sec id="s2-1"><title><italic>tp53</italic> deletion mutants spontaneously develop MPNSTs, angiosarcoma, germ cell tumors, and leukemia</title><p>Given the critical function of Tp53 as a tumor suppressor and the absence of a complete null allele in zebrafish, we created a <italic>tp53</italic> deletion mutant using two pairs of TALENs (Transcription Activator-Like Effector Nucleases) that cleaved at the 5’ and 3’ end of the <italic>tp53</italic> locus (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). One-cell stage CG1 syngeneic embryos (<xref ref-type="bibr" rid="bib28">Mizgireuv and Revskoy, 2006</xref>) were microinjected with mRNA encoding each TALEN pair and raised to adulthood. F1 embryos were screened by genomic PCR to identify a single founder line with deletion of 12.1 kb <italic>tp53</italic> genomic sequence (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). CG1 <italic>tp53<sup>wt/del</sup></italic> heterozygous fish were in-crossed and progeny assessed for Tp53 protein loss and the ability to undergo apoptosis following ionizing irradiation. As expected, homozygous <italic>tp53<sup>del/del</sup></italic> embryos lacked protein expression and were resistant to radiation-induced apoptosis (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B–D</xref>).</p><fig-group><fig id="fig1" position="float"><object-id pub-id-type="doi">10.7554/eLife.37202.002</object-id><label>Figure 1.</label><caption><title>Homozygous <italic>tp53<sup>del/del</sup></italic> zebrafish spontaneously develop a wide range of tumor types.</title><p>(<bold>A</bold>) <italic>tp53</italic> genomic locus and CG1 <italic>tp53<sup>del/del</sup></italic> allele. TALEN arms were designed to target the 5’ and 3’ genomic sequence of <italic>tp53</italic> (red). (<bold>B–M</bold>) CG1 <italic>tp53<sup>del/del</sup></italic> zebrafish develop leukemia (<bold>B–D</bold>), angiosarcoma (<bold>E–G</bold>), MPNSTs (<bold>H–J</bold>), and germ cell tumors (<bold>K–M</bold>). Whole animal images (<bold>B,E,H,K</bold>), hematoxylin/eosin (H and E) stained sections (<bold>C,D,F,G,I,L,M</bold>), and immunohistochemistry for Sox10 (<bold>J</bold>). Blast-like leukemia cells predominate in the kidney marrow and efface the renal tubules (black arrow, (<bold>D</bold>). (<bold>N</bold>) Tumor incidence in CG1 <italic>tp53<sup>del/del</sup></italic> zebrafish (n = 134). (<bold>O</bold>) Quantitation of tumor types that form in CG1 <italic>tp53<sup>del/del</sup></italic> mutant zebrafish by 55 weeks of life based on histology review (n = 51). (<bold>P–S</bold>) <italic>kRAS<sup>G12D</sup></italic>-induced embryonal rhabdomyosarcoma (ERMS) generated in CG1 <italic>tp53<sup>del/del</sup></italic> zebrafish. Whole animal bright field and GFP-epifluorescence overlap images (<bold>P</bold> and <bold>Q</bold>, respectively). H and E stained sections revealed features consistent with human ERMS (<bold>R,S</bold>). Scale bars equal 12.5 mm in whole animal images and 100 μm in histology images.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-37202-fig1-v1"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.37202.003</object-id><label>Figure 1—figure supplement 1.</label><caption><title><italic>tp53<sup>del/del</sup></italic> zebrafish survive at expected Mendelian ratios, lack Tp53 protein expression, and are resistant to irradiation-induced cell death.</title><p>(<bold>A</bold>) Survival of animals by genotype from a heterozygous <italic>tp53<sup>wt/del</sup></italic> in-cross. <italic>tp53</italic> homozygous wild-type (<italic>wt/wt</italic>), heterozygous (<italic>wt/del</italic>), and homozygous (<italic>del/del</italic>) mutant fish. (<bold>B</bold>) Western blot analysis at 24 hr post-fertilization (hpf) whole embryos. Actin is used as a loading control. (<bold>C–D</bold>) TUNEL staining performed on <italic>tp53<sup>wt/wt</sup></italic> and <italic>tp53<sup>del/del</sup></italic> embryos following gamma-irradiation at 24hpf (16 Gray) and fixation at 30hpf. Whole embryos images are shown for representative animals of each genotype (<bold>C</bold>). Quantification of TUNEL-positive cells within 1000 micron<sup>2</sup> area. Regions where cells were counted are outlined by the white boxes in panel C. p&lt;0.001 by Student’s T-test.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-37202-fig1-figsupp1-v1"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.37202.004</object-id><label>Figure 1—figure supplement 2.</label><caption><title>Tumor latency in <italic>tp53<sup>del/del</sup></italic> zebrafish.</title><p>Designation as assessed by histology review.</p><p><supplementary-material id="fig1s2sdata1"><object-id pub-id-type="doi">10.7554/eLife.37202.005</object-id><label>Figure 1—figure supplemenrt 2—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-37202-fig1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-37202-fig1-figsupp2-v1"/></fig></fig-group><p>Progeny from <italic>tp53<sup>wt/del</sup></italic> crosses were also raised to adulthood and assessed for viability and tumor onset over time. Both heterozygous <italic>tp53 <sup>wt/del</sup></italic> and homozygous <italic>tp53<sup>del/del</sup></italic> fish survived until adulthood at expected ratios (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). By 4 months of age<italic>, tp53<sup>del/del</sup></italic> zebrafish began to spontaneously develop tumors. Phenotypes of the earliest malignant <italic>tp53<sup>del/del</sup></italic> cohort were consistent with loss of osmoregulation and kidney damage. Histopathological analysis of these animals revealed features consistent with leukemia, including blast-like cells predominating in the kidney marrow and loss of kidney stromal architecture, including effacement of the renal tubules (<xref ref-type="fig" rid="fig1">Figure 1B–D</xref>, <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). Beginning by 7 months of age, a subset of <italic>tp53<sup>del/del</sup></italic> animals developed externally visible tumors and histology consistent with angiosarcoma and malignant peripheral nerve sheath tumors (MPNSTs) (<xref ref-type="fig" rid="fig1">Figure 1E–J</xref>, <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>) (<xref ref-type="bibr" rid="bib2">Berghmans et al., 2005</xref>; <xref ref-type="bibr" rid="bib5">Choorapoikayil et al., 2012</xref>; <xref ref-type="bibr" rid="bib35">Parant et al., 2010</xref>). A small subset of <italic>tp53<sup>del/del</sup></italic> fish also developed prominent externally visible abdominal masses that were diagnosed as germ cell tumors following histopathological analysis (n = 2, <xref ref-type="fig" rid="fig1">Figure 1K–M</xref>, <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>) (<xref ref-type="bibr" rid="bib33">Neumann et al., 2011</xref>). MPNST assignment was validated using IHC staining for <italic>sox10</italic>, which is a well-established clinical marker for this tumor type (<xref ref-type="fig" rid="fig1">Figure 1J</xref>) (<xref ref-type="bibr" rid="bib37">Shin et al., 2012</xref>). As expected, <italic>tp53<sup>wt/del</sup></italic> zebrafish infrequently developed tumors, which is consistent with studies in other <italic>tp53</italic> deficiency mouse models (<xref ref-type="bibr" rid="bib8">Donehower et al., 1992</xref>; <xref ref-type="bibr" rid="bib9">Harvey et al., 1993</xref>; <xref ref-type="bibr" rid="bib13">Jacks et al., 1994</xref>).</p><p>In total, 37% of <italic>tp53<sup>del/del</sup></italic> animals developed externally visible tumors by 12 months of age with a wider tumor spectrum than previously reported in homozygous <italic>tp53<sup>M214K</sup></italic> and <italic>tp53<sup>I166T</sup></italic> mutant zebrafish (<xref ref-type="fig" rid="fig1">Figure 1N,O</xref>) (<xref ref-type="bibr" rid="bib2">Berghmans et al., 2005</xref>; <xref ref-type="bibr" rid="bib35">Parant et al., 2010</xref>). For example, these point mutation models predominantly developed MPNSTs with only a rare, single melanoma being detected in homozygous animals (<xref ref-type="bibr" rid="bib2">Berghmans et al., 2005</xref>). Remarkably, the spectrum in <italic>tp53<sup>del/del</sup></italic> zebrafish was more similar to that reported in <italic>Tp53</italic>-null mice, with angiosarcomas and germ cell tumors occurring in both models (<xref ref-type="bibr" rid="bib8">Donehower et al., 1992</xref>; <xref ref-type="bibr" rid="bib9">Harvey et al., 1993</xref>; <xref ref-type="bibr" rid="bib13">Jacks et al., 1994</xref>). However, the predominance of T cell lymphomas seen in <italic>Tp53</italic>-null mice was not observed in <italic>tp53<sup>del/del</sup></italic> zebrafish, likely reflecting species differences in sensitivity to Tp53 loss in target cells. It is also possible that tumor types seen in <italic>Tp53</italic>-null mice exhibit longer latency in our model and would not manifest in the short-lived CG1 strain zebrafish. Finally, we also generated ERMS in <italic>tp53<sup>del/del</sup></italic> fish by microinjecting linearized human <italic>kRASG12D</italic> oncogene and <italic>GFP</italic> under the control of <italic>rag2</italic> promoter (<xref ref-type="fig" rid="fig1">Figure 1P,Q</xref>) (<xref ref-type="bibr" rid="bib18">Langenau et al., 2007</xref>). Histopathological analysis of transgene-induced <italic>tp53<sup>del/del</sup></italic> ERMS showed consistent morphology with the spindle-variant of human ERMS (<xref ref-type="fig" rid="fig1">Figure 1R,S</xref>) (<xref ref-type="bibr" rid="bib18">Langenau et al., 2007</xref>).</p></sec><sec id="s2-2"><title><italic>tp53<sup>del/del</sup></italic> tumors are transplantable</title><p>One major advantage of generating <italic>tp53<sup>del/del</sup></italic> mutations in the CG1 syngeneic stain of zebrafish is the ease with which tumors can be used in cell transplantation assays. Primary MPNSTs that arose in the eye were dissected from euthanized <italic>tp53<sup>del/del</sup></italic> animals and orthotopically transplanted into the equivalent periocular space or into the peritoneum of CG1-strain recipient fish (n = 2 primary tumors, n = 9 recipient fish total, 2 × 10<sup>4</sup> cells/fish). All recipient animals engrafted tumor with histology similar to the primary disease (<xref ref-type="fig" rid="fig2">Figure 2A–E</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). To more easily track tumor cells in host animals, we also crossed <italic>tp53<sup>del/del</sup></italic> animals into CG1 syngeneic <italic>ubi</italic>:GFP transgenic zebrafish. We successfully engrafted <italic>tp53<sup>del/del</sup></italic> angiosarcomas into CG1-recipient animals and <italic>ubi:</italic>GFP+ tumor cells were easily traceable in non-fluorescent recipients (n = 3 primary tumors, n = 8 of 9 transplant fish developed tumors, <xref ref-type="fig" rid="fig2">Figure 2F–I</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). Finally, <italic>ubi</italic>:GFP+ leukemias were also assessed by cell transplantation. Specifically, blood cells were engrafted into non-irradiated CG1 strain fish (2.5 × 10<sup>4</sup> cells/intraperitoneal injection). In total, five of five primary leukemias engrafted into recipient fish with GFP+ cells disseminating widely throughout the animal by 60 days post-transplantation (n = 5 primary leukemias, n = 25 of 25 animals engrafted leukemia, <xref ref-type="fig" rid="fig2">Figure 2J–M</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). Whole animal imaging and flow cytometric analysis revealed that GFP+ cells also invaded the recipient kidney marrow, the site of hematopoiesis in adult zebrafish (<xref ref-type="fig" rid="fig2">Figure 2M,N</xref>). Leukemic cells consisted of as much as 45% of the reconstituted marrow in transplanted fish (<xref ref-type="fig" rid="fig2">Figure 2N</xref>, n = 3 independent primary leukemias analyzed). To more closely observe leukemia cell morphology, FACs sorted GFP+ leukemia cells were assessed by cytospin and Wright/Giemsa staining (<xref ref-type="fig" rid="fig2">Figure 2O–R</xref>). The leukemic cells were large with prominent nucleoli and abundant, vacuolated cytoplasm, consistent with a rare, high-grade aggressive NK cell leukemia. In the context of gene expression profiling (outlined below), these leukemias were also similarly classified as aggressive NK cell-like leukemia, suggesting important roles for <italic>Tp53</italic> in initiation of leukemias of NK cell origin (<xref ref-type="fig" rid="fig2">Figure 2Q,R</xref>). Finally, GFP-labeled <italic>kRASG12D</italic>-induced <italic>tp53<sup>del/del</sup></italic> ERMS were readily transplantable when engrafted into syngeneic recipient fish (n = 11 primary tumors analyzed, n = 47/49 fish engrafted, <xref ref-type="fig" rid="fig2">Figure 2S–V</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). Histology was similar between primary and transplanted MPNSTs, angiosarcomas, leukemias and ERMS (<xref ref-type="fig" rid="fig2">Figure 2B,C,E,I,M,V</xref>).</p><fig-group><fig id="fig2" position="float"><object-id pub-id-type="doi">10.7554/eLife.37202.006</object-id><label>Figure 2.</label><caption><title><italic>tp53<sup>del/del</sup></italic> tumors efficiently transplant into syngeneic CG1 strain zebrafish.</title><p>(<bold>A–E</bold>) A primary <italic>tp53<sup>del/del</sup></italic> MPNSTs that formed in the eye transplanted orthotopically into the periocular space (<bold>A–C</bold>) or into the peritoneum of CG1-strain recipient fish (<bold>D–E</bold>). Intraperitoneal injection (i/p). (<bold>F–I</bold>) <italic>tp53<sup>del/del</sup></italic> Tg(<italic>ubi</italic>:GFP)-positive angiosarcoma. Primary tumor-bearing fish (<bold>F–G</bold>) and transplanted animal (<bold>H–I</bold>). (<bold>J–R</bold>) <italic>tp53<sup>del/del</sup></italic> Tg(<italic>ubi</italic>:GFP)-positive leukemia. Primary leukemia (<bold>J–K</bold>) and transplanted leukemia shown at 20 days post-transplantation (<bold>L–R</bold>). Whole kidney marrow was isolated from leukemia-engrafted fish and analyzed by FACS (<bold>N–O</bold>). (<bold>N</bold>) Forward and side scatter plot of whole kidney marrow of unlabeled CG1 host animal to assess <italic>ubi:</italic>GFP-positive <italic>tp53<sup>del/del</sup></italic> leukemia cells following transplantation. (<bold>O</bold>) Analysis of GFP+ <italic>ubi:</italic>GFP-positive <italic>tp53<sup>del/del</sup></italic> leukemia cells following FACS. Purity was ≥90%. (<bold>P–R</bold>) Cytospins and Wright/Giemsa staining of whole kidney marrow cells isolated from wildtype fish (<bold>P</bold>) compared with FACS sorted GFP+ cells from two representative aggressive NK cell-like leukemias, showing large blastic cells with abundant basophilic, vacuolated cytoplasm (<bold>Q–R</bold>). (<bold>S–V</bold>) Embryonal rhabdomyosarcoma arising in <italic>tp53<sup>del/del</sup></italic> fish micro-injected at the one-cell stage with linearized <italic>rag2</italic>:kRAS<sup>G12D</sup> + <italic>rag2</italic>:GFP. Primary (<bold>S</bold>), transplanted (2°) (<bold>T</bold>), and serially transplanted ERMS (3°) (<bold>U,V</bold>). Whole animal bright-field images (<bold>A,D,F,J</bold>) and merged GFP-fluorescence images (<bold>G,H,K,L,S–U</bold>). Hematoxylin and eosin stained sections of engrafted tumors (<bold>B–C,E, I, M,V</bold>). Scale bars are 5 mm in whole animal images and 100 μm for histology images.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-37202-fig2-v1"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.37202.007</object-id><label>Figure 2—figure supplement 1.</label><caption><title>Engraftment of <italic>tp53<sup>del/del</sup></italic> tumors into CG1 recipient zebrafish.</title><p>Engraftment was scored at &gt;20 days post transplantation. i.p. intraperitoneal.</p><p><supplementary-material id="fig2s1sdata1"><object-id pub-id-type="doi">10.7554/eLife.37202.008</object-id><label>Figure 2—figure supplemenrt 1—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-37202-fig2-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-37202-fig2-figsupp1-v1"/></fig></fig-group></sec><sec id="s2-3"><title>Gene expression analysis of <italic>tp53<sup>del/del</sup></italic> tumors arising in transplant recipient fish</title><p>We next profiled the transcriptome of tumor cells isolated from fish transplanted with <italic>tp53<sup>del/del</sup></italic> MPNSTs, angiosarcomas, leukemias, a germ cell tumor and <italic>kRAS<sup>G12D</sup>-</italic>induced ERMS by Poly(A)<sup>+</sup> RNA-sequencing (RNAseq). MPNSTs and the germ cell tumor were analyzed from bulk tumor isolated from non-GFP labeled animals, whereas angiosarcomas, leukemias, and ERMS were FACS sorted from engrafted GFP-labeled tumors (purity and viability &gt;85%). Bulk mRNA from three independent wild-type CG1 strain fish was also sequenced and used as a control. Principal component analysis identified six distinct clusters corresponding to whole CG1 syngeneic fish, leukemia, MPNSTs, angiosarcomas, germ cell tumor and ERMS (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). By comparing gene expression among different tumor types, unique tumor-specific expression profiles were identified and each assessed for overlap with gene sets found in the Molecular Signatures Database (MSigDB, <xref ref-type="fig" rid="fig3">Figure 3B,C</xref>, <xref ref-type="supplementary-material" rid="fig3sdata1">Figure 3—source datas 1</xref>–<xref ref-type="supplementary-material" rid="fig3sdata3">3</xref>). For example, the upregulated leukemia gene set identified in zebrafish was significantly enriched for GO terms associated with immune system processes, leukocyte activation, immune response and lymphocyte activation. By contrast, angiosarcomas were enriched in GO gene sets associated with vasculature, blood vessel morphogenesis and cellular proliferation. The germ cell tumor showed enrichment of GO gene sets associated with sexual reproduction and gamete formation. As expected, ERMS shared significant overlap of gene signatures with muscle structure, muscle contraction and muscle development.</p><fig-group><fig id="fig3" position="float"><object-id pub-id-type="doi">10.7554/eLife.37202.009</object-id><label>Figure 3.</label><caption><title>Gene expression analysis of <italic>tp53<sup>del/del</sup></italic> tumors.</title><p>(<bold>A</bold>) Principal component analysis (PCA) of gene expression profiles from whole CG1 syngeneic fish, MPNSTs, a germ cell tumor, and FACS sorted GFP+ leukemia, angiosarcomas, and ERMS. All tumor samples were obtained following engraftment in CG1 syngeneic recipient fish. (<bold>B</bold>) Heat map of genes differentially expressed with respect to controls identifies molecularly defined tumor groups. (<bold>C</bold>) Upregulated genes identified within each tumor type are enriched for Molecular Signature Database (MSigDB) signatures consistent with the expected tissue of origin. (<bold>D</bold>) NK cell leukemias are enriched for gene signatures identified from normal NK and NKL cells in the kidney marrow and NK cells isolated from <italic>rag1<sup>-/-</sup>, tg(lck:GFP)</italic> transgenic fish (NK cells*). For each analysis, enrichment is shown for the top 30 lineage-restricted genes identified from single-cell transcriptional profiling of transgenic cells using SMARTseq2 (denoted by asterisks) or unsorted cells using InDrops single-cell RNA sequencing approaches. (<bold>E</bold>) Heat map highlighting NK lineage genes significantly upregulated in <italic>tp53<sup>del/del</sup></italic> leukemias when compared to all other tumor types analyzed. [log<sub>2</sub>(fold-change)]. Angiosarcoma (AS) and germ cell tumor (GC).</p><p><supplementary-material id="fig3sdata1"><object-id pub-id-type="doi">10.7554/eLife.37202.014</object-id><label>Figure 3—source data 1.</label><caption><title>Genes and expression values for heatmap rendering shown in <xref ref-type="fig" rid="fig3">Figure 3B</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-37202-fig3-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig3sdata2"><object-id pub-id-type="doi">10.7554/eLife.37202.015</object-id><label>Figure 3—source data 2.</label><caption><title>Top 500 transcripts differentially regulated in each tumor subtype identified by RNA sequencing analysis.</title><p>These gene lists were used to assess overlap with the GSEA signature database.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-37202-fig3-data2-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig3sdata3"><object-id pub-id-type="doi">10.7554/eLife.37202.016</object-id><label>Figure 3—source data 3.</label><caption><title>Table showing GSEAsig analysis for data rendered in <xref ref-type="fig" rid="fig3">Figure 3C</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-37202-fig3-data3-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig3sdata4"><object-id pub-id-type="doi">10.7554/eLife.37202.017</object-id><label>Figure 3—source data 4.</label><caption><title>Differential gene expression for <italic>tp53<sup>del/del</sup></italic> and <italic>tp53<sup>M214K/M214K</sup></italic> MPNST.</title><p>Significant overlap was observed for both commonly up-regulated (p=4e-321) and down-regulated (p=5e-182) genes. A fold change of log2(FC) ≥2 was considered differential and statistical significance was assessed as p≤0.05 with a one-sided Fisher’s exact test.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-37202-fig3-data4-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig3sdata5"><object-id pub-id-type="doi">10.7554/eLife.37202.018</object-id><label>Figure 3—source data 5.</label><caption><title>Genes used for analysis shown in <xref ref-type="fig" rid="fig3">Figure 3D</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-37202-fig3-data5-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-37202-fig3-v1"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.37202.010</object-id><label>Figure 3—figure supplement 1.</label><caption><title>Zebrafish cancers share common gene expression with human tumors and confirmation of NK-cell linage derivation for <italic>tp53<sup>del/del</sup></italic> leukemias.</title><p>(<bold>A–C</bold>) GSEA analysis comparing zebrafish <italic>tp53<sup>del/del</sup></italic> tumors to human counterparts. (<bold>A</bold>) Human angiosarcoma (FDR q-value = 0.001), (<bold>B</bold>) human MPNST (FDR q-value = 0.00433526), and (<bold>C</bold>) human ERMS (FDR q-value = 0) gene sets are significantly enriched in the corresponding zebrafish <italic>tp53<sup>del/del</sup></italic> tumors. (<bold>D</bold>) Heat map depicting differential gene expression in zebrafish <italic>tp53<sup>del/del</sup></italic> leukemias compared to whole CG1 control animals. Gene-expression defines <italic>tp53<sup>del/del</sup></italic> leukemias based on lineage signatures previously generated using InDrop and SMARTseq (asterisk) sequencing approaches (<xref ref-type="bibr" rid="bib43">Tang et al., 2017</xref>). (<bold>E</bold>) Expression of the top 200 <italic>tp53<sup>del/del</sup></italic> ANKL-like genes assessed in the SMARTseq dataset from <xref ref-type="bibr" rid="bib43">Tang et al. (2017)</xref>. HSC/progenitors were isolated as <italic>cd41:</italic>GFP<sup>low</sup> cells from transgenic zebrafish, T cells from <italic>tg(lck:GFP)</italic> transgenic zebrafish, NK cells from <italic>rag1-/-, tg(lck:GFP)</italic> transgenic zebrafish, myeloid cells from <italic>tg(mpx:EGFP)</italic> transgenic zebrafish, B cells from marrow-derived <italic>tg(rag2:GFP)</italic> transgenic zebrafish, and HSCs from <italic>tg(runx1<sup>+23</sup>:GFP)</italic> transgenic zebrafish. The <italic>tp53<sup>del/del</sup></italic> leukemia gene expression signature was significantly enriched only in the NK cells (log2(TPM+ 1)≥2, p-value=0.015, one-sided binomial test).</p><p><supplementary-material id="fig3s1sdata1"><object-id pub-id-type="doi">10.7554/eLife.37202.011</object-id><label>Figure 3—figure supplement 1—source data 1.</label><caption><title>GSEA report and human tumor gene expression signatures used for GSEA comparing <italic>tp53<sup>del/del</sup></italic> angiosarcoma, MPNST and ERMS to their human counterparts.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-37202-fig3-figsupp1-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig3s1sdata2"><object-id pub-id-type="doi">10.7554/eLife.37202.012</object-id><label>Figure 3—figure supplement 1—source data 2.</label><caption><title>Differential gene expression for <italic>tp53<sup>del/del</sup></italic> leukemias with respect to blood cells and kidney cells shown in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D</xref>.</title><p>Gene identifications correspond to SMARTseq and InDrop single cell sequencing from <xref ref-type="bibr" rid="bib43">Tang et al. (2017)</xref>, as indicated.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-37202-fig3-figsupp1-data2-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig3s1sdata3"><object-id pub-id-type="doi">10.7554/eLife.37202.013</object-id><label>Figure 3—figure supplement 1—source data 3.</label><caption><title>Genes used for analysis shown in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-37202-fig3-figsupp1-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-37202-fig3-figsupp1-v1"/></fig></fig-group><p>To assess similarities between <italic>tp53<sup>del/del</sup></italic> tumors and human, we next assessed if zebrafish tumors express tumor-specific gene signatures identified from human angiosarcoma (<xref ref-type="bibr" rid="bib1">Andersen et al., 2013</xref>), MPNST (<xref ref-type="bibr" rid="bib16">Kolberg et al., 2015</xref>) and ERMS (experimentally determined using GEO:GSE108022) (<xref ref-type="supplementary-material" rid="fig3s1sdata1">Figure 3—figure supplement 1—source data 1</xref>). Using Gene set enrichment analysis (GSEA) (<xref ref-type="bibr" rid="bib29">Mootha et al., 2003</xref>; <xref ref-type="bibr" rid="bib40">Subramanian et al., 2005</xref>), we identified significant enrichment of signatures associated with human angiosarcoma (FDR q-value = 0.001, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>), MPNST (FDR q-value = 0.00433526, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>), and ERMS (FDR q-value = 0, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C</xref>) in the corresponding zebrafish <italic>tp53<sup>del/del</sup></italic> tumors but not other tumor types (<xref ref-type="supplementary-material" rid="fig3s1sdata1">Figure 3—figure supplement 1—source data 1</xref>). Taken together, these data reveal conserved gene expression programs associated with both the predicted cells of origin and the corresponding human cancer counterpart.</p><p>Given that GSEAsig analysis failed to assign leukemias to a specific lineage, we next assessed if these tumors were enriched for signatures associated with normal blood cell lineages identified previously by our group using single-cell RNA sequencing of the zebrafish marrow (<xref ref-type="bibr" rid="bib43">Tang et al., 2017</xref>). Using these lineage-specific gene sets, we found that <italic>tp53<sup>del/del</sup></italic> leukemias expressed markers indicative of NK and NK-like cells but largely failed to express genes associated with other hematopoietic cell lineages (<xref ref-type="fig" rid="fig3">Figure 3D</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D,E</xref>). To independently confirm our results, we next identified the top 200 most differentially regulated genes in leukemias compared to all other tumor types and assessed if these genes were differentially expressed in each zebrafish blood lineage. Significant enrichment was only observed in NK cells (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E</xref>, p=0.015, one-sided binomial test), supporting a NK cell origin of <italic>tp53<sup>del/del</sup></italic> leukemias. Importantly, <italic>tp53<sup>del/del</sup></italic> NK cell-like leukemias also expressed well-known genes commonly associated with human NK cells, including <italic>il2ga</italic> and <italic>b, jak3</italic>, <italic>perforins 2,7,</italic> and <italic>8,</italic> and these genes were highly up-regulated when compared to all other tumor types in our analysis (<xref ref-type="fig" rid="fig3">Figure 3E</xref>).</p><p>In humans, aggressive NK cell leukemias (ANKLs) have a very poor prognosis and often express perforins but lack markers of mature T- and B- cell lineages (<xref ref-type="bibr" rid="bib22">Liang and Graham, 2008</xref>; <xref ref-type="bibr" rid="bib41">Suzuki and Nakamura, 1999</xref>). In human disease, ANKLs are associated with Epstein-Barr virus infection, however, CD3<sup>-</sup>/CD4<sup>-</sup>/CD56<sup>+</sup>/CD13<sup>-</sup>/CD33<sup>-</sup> leukemias without EBV infection and intact germline configured T-cell receptor and immunoglobulin have been reported (<xref ref-type="bibr" rid="bib22">Liang and Graham, 2008</xref>). Interestingly, both <italic>TP53</italic> point mutations and deletions have been identified in human ANK cell leukemias, suggesting a role for TP53 in pathogenesis of this disease (<xref ref-type="bibr" rid="bib39">Soliman et al., 2014</xref>; <xref ref-type="bibr" rid="bib50">Yagita et al., 2000</xref>). Yet, to date no in vivo animal models of ANKL have been reported precluding direct functional assessment of TP53 loss in eliciting transformation of NK cells.</p><p>Given that tumor onset and spectrum differ based on the nature of <italic>Tp53</italic> mutation or deletion in mice, we next compared gene expression between MPNSTs arising in <italic>tp53<sup>del/del</sup></italic> and tp53<sup>M214K/M214K</sup> mutant zebrafish (<xref ref-type="supplementary-material" rid="fig3sdata4">Figure 3—source data 4</xref>). As may be expected, we found significant overlap in expression between homozygous <italic>tp53</italic> deletion and point-mutant MPNSTs when compared to whole fish (p=4e-321 for up-regulated genes and p=5e-182 for down-regulated genes, one-sided Fisher’s exact test (<xref ref-type="supplementary-material" rid="fig3sdata4">Figure 3—source data 4</xref>), confirming the previously described loss-of-function activity for <italic>tp53<sup>M214K</sup></italic> (<xref ref-type="bibr" rid="bib2">Berghmans et al., 2005</xref>). Interestingly, differences in gene expression were also noted when comparing these tumors, likely arising from differences in the underlying mutations (<xref ref-type="supplementary-material" rid="fig3sdata4">Figure 3—source data 4</xref>), which are known to differentially affect Tp53 function and tumor etiology in genetically engineered mouse models.</p></sec><sec id="s2-4"><title><italic>tp53<sup>del/del</sup></italic> ERMS display increased metastasis but did not alter cancer stem cell number</title><p>TP53 has roles in regulating self-renewal of normal stem cells and human cancer cells, including acute myeloid leukemia and breast cancer (<xref ref-type="bibr" rid="bib6">Cicalese et al., 2009</xref>; <xref ref-type="bibr" rid="bib27">Meletis et al., 2006</xref>; <xref ref-type="bibr" rid="bib47">TeKippe et al., 2003</xref>; <xref ref-type="bibr" rid="bib51">Zhao et al., 2010</xref>). Thus, we predicted that <italic>tp53</italic> loss may affect the overall frequency of self-renewing cancer stem cells in zebrafish ERMS. To test this hypothesis, GFP+ ERMS cells were isolated by FACS and injected at limiting dilution into the peritoneum of CG1 recipients (1 × 10<sup>4</sup>–10 cells/recipient, <xref ref-type="fig" rid="fig2">Figure 2T</xref>). Animals were followed for 90 days for engraftment using whole animal epi-fluorescent imaging. Unexpectedly, kRAS<sup>G12D</sup>-induced tumors harboring wild-type <italic>tp53</italic> had similar frequency of tumor-propagating stem cells when compared with those of <italic>tp53<sup>del/del</sup></italic> ERMS (n ≥ 3 tumors analyzed per genotype, p=0.647 EDLA analysis, <xref ref-type="table" rid="table1">Table 1</xref>). We concluded that Tp53 loss-of-function does not alter the overall frequency of tumor-sustaining, cancer stem cells in ERMS, which contrasts with previous studies that defined major roles for NOTCH1, MYF5/MYOD, and WNT signaling in regulating self-renewal and the overall number of tumor sustaining cell types in rhabdomyosarcoma (<xref ref-type="bibr" rid="bib3">Chen et al., 2014</xref>; <xref ref-type="bibr" rid="bib10">Hayes et al., 2018</xref>; <xref ref-type="bibr" rid="bib12">Ignatius et al., 2017</xref>; <xref ref-type="bibr" rid="bib48">Tenente et al., 2017</xref>).</p><table-wrap id="table1" position="float"><object-id pub-id-type="doi">10.7554/eLife.37202.019</object-id><label>Table 1.</label><caption><title>Results from limiting dilution cell transplantation experiments comparing engraftment potential of <italic>tp53<sup>wt/wt</sup></italic> and <italic>tp53<sup>del/del</sup></italic> kRAS<sup>G12D</sup>-induced ERMS.</title></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="5" valign="top"><italic>tp53<sup>wt/wt</sup> + rag2</italic>:kRASG12D ERMS</th></tr><tr><th valign="top">Cell #</th><th valign="top">Tumor 1</th><th valign="top">Tumor 2</th><th valign="top">Tumor 3</th><th valign="top">Tumor 3</th></tr></thead><tbody><tr><td valign="top">10000</td><td valign="top">7 of 7</td><td valign="top">5 of 6</td><td valign="top">6 of 6</td><td valign="top">6 of 6</td></tr><tr><td valign="top">1000</td><td valign="top">2 of 6</td><td valign="top">2 of 7</td><td valign="top">6 of 8</td><td valign="top">1 of 8</td></tr><tr><td valign="top">100</td><td valign="top">0 of 9</td><td valign="top">0 of 8</td><td valign="top">1 of 8</td><td valign="top">0 of 8</td></tr><tr><td rowspan="2" valign="top">TPC#</td><td valign="top">1 in 2832</td><td valign="top">1 in 4810</td><td valign="top">1 in 726</td><td valign="top">1 in 7388</td></tr><tr><td colspan="4" valign="top">1 in 3495 (2291–5333)</td></tr><tr><td colspan="5" valign="top"><italic>tp53<sup>del/del</sup> + rag2</italic>:kRASG12D ERMS</td></tr><tr><td valign="top">Cell #</td><td valign="top">Tumor 1</td><td valign="top">Tumor 2</td><td valign="top">Tumor 3</td><td/></tr><tr><td valign="top">10000</td><td valign="top">3 of 5</td><td valign="top">5 of 6</td><td valign="top">6 of 6</td><td/></tr><tr><td valign="top">1000</td><td valign="top">3 of 4</td><td valign="top">3 of 5</td><td valign="top">0 of 7</td><td/></tr><tr><td valign="top">100</td><td valign="top">3 of 9</td><td valign="top">3 of 7</td><td valign="top">1 of 8</td><td/></tr><tr><td rowspan="2" valign="top">TPC#</td><td valign="top">1 in 3546</td><td valign="top">1 in 2228</td><td valign="top">1 in 3640</td><td/></tr><tr><td colspan="4" valign="top">1 in 3038 (1739–5307), p=0.647</td></tr></tbody></table></table-wrap><p><italic>TP53</italic> loss is predictive of poor outcome in human ERMS (<xref ref-type="bibr" rid="bib36">Seki et al., 2015</xref>); however, given that <italic>tp53</italic> loss did not regulate the overall frequency of ERMS stem cells in zebrafish, we reasoned that loss of Tp53 might rather affect tumor invasion and metastasis. To test this hypothesis, we undertook tumor cell transplantation experiments whereby GFP-labeled tumor cells were injected into the dorsolateral musculature of recipient fish and animals monitored for spread into the viscera using epifluoresence whole animal imaging (n = 5 <italic>tp53<sup>wt/wt</sup></italic> and n = 11 <italic>tp53<sup>del/del</sup></italic> ERMS, n = 7–15 recipient fish per tumor,&gt;2×10<sup>4</sup> cells/recipient) (<xref ref-type="bibr" rid="bib44">Tang et al., 2016</xref>). As expected, all animals developed GFP+ masses at the site of primary injection (<xref ref-type="fig" rid="fig4">Figure 4A,D</xref>, n = 160). Tumor growth was followed for up to 30 days after cell transplantation and animals were assessed for 1) local infiltrative disease defined by growth well beyond but contiguous with the primary site, or 2) metastasis defined by growth at sites unconnected to the primary lesion and/or associated with infiltration into organs within the peritoneal cavity (<xref ref-type="bibr" rid="bib44">Tang et al., 2016</xref>). Through serial imaging of engrafted fish over time, we identified only rare metastatic lesions in zebrafish engrafted with <italic>tp53<sup>wt/wt</sup></italic> ERMS (n = 5 of 58 engrafted animals, <xref ref-type="fig" rid="fig4">Figure 4A–F</xref>). By contrast, <italic>tp53<sup>del/del</sup></italic> ERMS were highly aggressive and displayed elevated local invasion and disseminated metastatic disease (n = 28 of 102 engrafted fish had metastatic ERMS, p=0.003, one-sided Fisher’s exact test, <xref ref-type="fig" rid="fig4">Figure 4I</xref>). These metastatic lesions were confirmed on paraffin-embedded sections using both hematoxylin/eosin staining and anti-GFP antibody IHC (<xref ref-type="fig" rid="fig4">Figure 4G,H</xref>). Thus, our in vivo experiments demonstrate an important consequence for <italic>tp53</italic> loss in stimulating local infiltration and metastasis, revealing a property that may account for poor outcome in RMS patients with TP53 pathway deregulation.</p><fig id="fig4" position="float"><object-id pub-id-type="doi">10.7554/eLife.37202.020</object-id><label>Figure 4.</label><caption><title><italic>tp53<sup>del/del</sup> kRAS<sup>G12D</sup>-</italic>induced ERMS have increased invasion and metastasis.</title><p>(<bold>A–F</bold>) Whole animal fluorescent images of CG1-strain fish engrafted into the dorsolateral musculature with non-disseminated (<bold>A–C</bold>) and disseminated ERMS (<bold>D–F</bold>). Days post transplantation (dpt). White lines demarcate GFP+ tumor area. White arrowheads show site of injection and yellow arrowheads denote metastatic lesions. (<bold>G</bold>) H and E and (<bold>H</bold>) GFP immunohistological staining of fish engrafted with metastatic <italic>tp53<sup>del/del</sup></italic> kRAS<sup>G12D</sup>-induced ERMS. (<bold>I</bold>) Quantification of growth confined to site of injection (green bars) and compared with animals that exhibited local invasion or metastatic ERMS following tumor engraftment until fish were moribund. X-axis identifies 5 <italic>tp53<sup>wt/wt</sup></italic> and 11 <italic>tp53<sup>del/del</sup></italic> ERMS primary tumors that were transplanted into wild-type CG1 syngeneic host zebrafish. p=0.003, one-sided Fisher’s exact test. Scale bars denote 5 mm.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-37202-fig4-v1"/></fig><p>Taken together, our work has defined syngeneic zebrafish as a novel model to assess Tp53 loss-of-function phenotypes and has generated a wide array of cancer types now available for study by the community. This is particularly important for modeling angiosarcoma and aggressive NK cell leukemias for which readily available tp53-deficient zebrafish models are lacking. To date, our <italic>tp53<sup>del/del</sup></italic> zebrafish is the first description of any animal model of aggressive NK cell-like leukemia, highlighting the importance of Tp53 loss in the genesis of these leukemias and opening exciting new avenues of future study. Finally, our work in embryonal rhabdomyosarcoma revealed that Tp53 loss likely has major impacts on regulating ERMS invasion and metastasis, without altering the overall frequency of relapse driving cancer stem cells. Such findings likely account for why human RMS are more aggressive following TP53 pathway disruption (<xref ref-type="bibr" rid="bib36">Seki et al., 2015</xref>). This work is important, because unlike available genetically engineered mouse models and human ERMS xenografts, zebrafish ERMS are metastatic, which can be readily quantified and visualized in vivo. Future experiments will likely utilize the <italic>tp53<sup>del/del</sup></italic> model to study cancer stem cell self-renewal pathways and metastatic progression in a wider array of tumor types including angiosarcoma, MPNSTs, and available transgenic models that require <italic>tp53</italic> loss.</p></sec></sec><sec id="s3" sec-type="methods"><title>Methods and materials</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th>Reagent type (species) <break/>or resource</th><th>Designation</th><th>Source or reference</th><th>Identifiers</th><th>Additional <break/>information</th></tr></thead><tbody><tr><td>Genetic reagent <break/>(<italic>danio rerio</italic>)</td><td>CG1</td><td><xref ref-type="bibr" rid="bib28">Mizgireuv and Revskoy (2006)</xref></td><td/><td/></tr><tr><td>Genetic reagent <break/>(<italic>danio rerio</italic>)</td><td><italic>rag2<sup>E450fs/E450fs</sup></italic></td><td><xref ref-type="bibr" rid="bib42">Tang et al. (2014)</xref></td><td/><td/></tr><tr><td>Antibody</td><td>anti-tp53 (zebrafish)</td><td>Abcam</td><td>ab77813, RRID: <break/><ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10864112">AB_10864112</ext-link></td><td>WB 5 ug/mL</td></tr><tr><td>Antibody</td><td>anti-Actin</td><td>Sigma</td><td>A2066, RRID: <break/><ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_476693">AB_476693</ext-link></td><td>WB 1:200</td></tr><tr><td>Antibody</td><td>anti-mouse HRP</td><td>Sigma</td><td>NA931, RRID: <break/><ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_772210">AB_772210</ext-link></td><td>WB 1:1000</td></tr><tr><td>Antibody</td><td>anti-rabbit HRP</td><td>Cell Signalling <break/>Technology</td><td>7074, RRID: <break/><ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB2099233">AB2099233</ext-link></td><td>WB 1:1000</td></tr><tr><td>Recombinant <break/>DNA construct</td><td><italic>rag2:kRASG12D</italic></td><td><xref ref-type="bibr" rid="bib18">Langenau et al. (2007)</xref></td><td/><td/></tr><tr><td>Recombinant <break/>DNA construct</td><td><italic>rag2:GFP</italic></td><td><xref ref-type="bibr" rid="bib18">Langenau et al. (2007)</xref> <break/><xref ref-type="bibr" rid="bib19">Langenau et al. (2008)</xref></td><td/><td/></tr><tr><td>Recombinant <break/>DNA construct</td><td><italic>ubi:GFP</italic></td><td><xref ref-type="bibr" rid="bib30">Mosimann et al. (2011)</xref></td><td/><td/></tr><tr><td>Commercial <break/>assay or kit</td><td>In situ Cell Death <break/>Detection Kit, TMR red</td><td>Sigma</td><td>12156792910</td><td/></tr></tbody></table></table-wrap><sec id="s3-1"><title>Animals</title><p>Zebrafish used in this work included: CG1 strain zebrafish (<xref ref-type="bibr" rid="bib28">Mizgireuv and Revskoy, 2006</xref>), CG1-strain Tg(<italic>ubi</italic>:GFP) animals that were generated using Tol2-mediated transgenesis (<xref ref-type="bibr" rid="bib15">Kawakami et al., 2000</xref>; <xref ref-type="bibr" rid="bib30">Mosimann et al., 2011</xref>), and <italic>rag2<sup>E450fs/E450fs</sup>;casper</italic> strain zebrafish that were used in a subset of ERMS metastasis assays. All animal studies were approved by the Massachusetts General Hospital Subcommittee on Research Animal Care under the protocol #2011 N-000127.</p></sec><sec id="s3-2"><title>Generation of <italic>tp53<sup>del/del</sup></italic> zebrafish using TALENS</title><p>Four TALEN pairs (two pairs each flanking the <italic>tp53</italic> gene locus in <italic>D. rerio</italic>) were designed to generate a ~12.1 kb deletion encompassing the entire <italic>tp53</italic> coding sequence. Mojo Hand (<ext-link ext-link-type="uri" xlink:href="http://talendesign.org">http://talendesign.org</ext-link>) was used to design eight 15-mer repeat variable di-residue (RVD) TALENs with a 15 to 18 bp spacer (<xref ref-type="bibr" rid="bib25">Ma et al., 2013</xref>; <xref ref-type="bibr" rid="bib32">Neff et al., 2013</xref>). Each TALEN pair was designed to target a unique restriction site that could be used to determine TALEN cutting efficacy by restriction fragment length polymorphism (RFLP) analysis. All TALEN constructs were synthesized with the Golden Gate method using the RCIscript-GoldyTALEN scaffold (Addgene, <ext-link ext-link-type="uri" xlink:href="https://www.addgene.org/Stephen_Ekker/">https://www.addgene.org/Stephen_Ekker/</ext-link>, ID# 38142) (<xref ref-type="bibr" rid="bib25">Ma et al., 2013</xref>; <xref ref-type="bibr" rid="bib32">Neff et al., 2013</xref>). The RVDs NI, HD, NG and NN (recognizing A, C, T and G bases, respectively) were used to construct TALENs. Intermediate constructs containing RVDs for positions 1 to 10 were synthesized in the pFUS_A receiver plasmid in the first reaction. Pre-synthesized pFUS_B4 plasmids were then selected based on the target sequence. The library of 256 pFUS_B4 plasmids is available through Addgene (<ext-link ext-link-type="uri" xlink:href="https://www.addgene.org/Stephen_Ekker/">https://www.addgene.org/Stephen_Ekker/</ext-link>, Kit # 1000000038). The completed pFUS_A and pFUS_B4 as well as the last half-repeat plasmid (pLR-NI, -HD, -NN or -NG) were combined in the second Golden Gate reaction in the RCIscript-GoldyTALEN expression vector that has T3 promoter. The completed constructs were linearized using SacI, and mRNA was in vitro transcribed using the mMESSAGE mMACHINE T3 Transcription Kit (Thermo Fisher Scientific, cat. no. AM1348). Large deletions encompassing the <italic>tp53</italic> locus were engineered through co-injection of TALEN pairs targeting the <italic>tp53</italic> 5’UTR and 3’UTR. Genotyping was performed using standard PCR: <italic>tp53</italic> forward 5’-CACAGCAAGGACACATCTGC-3’, <italic>tp53<sup>del</sup></italic> reverse 5’-AGATCAGTGCTTGTATTGTATCAGTTT-3’, <italic>tp53<sup>wt</sup></italic> reverse 5’-GATCGCTCAGAGTCGCAAA-3’</p></sec><sec id="s3-3"><title>Embryonic protein extraction and western blotting</title><p>24 hpf embryos of the respective genotypes were dissociated in PBS, spun down at 1000xg to de-yolk samples, and lysed in 10% SDS buffer. Western blot was performed using anti-tp53 (ab77813, Abcam) and anti-actin (A2066, Sigma) antibodies.</p></sec><sec id="s3-4"><title>Apoptosis assay</title><p>Embryos were raised at 28°C and gamma-irradiated at 24 hpf. At 30 hpf embryos were fixed overnight in 4% paraformaldehyde followed by staining using the In Situ Cell Death Detection Kit, TMR Red (Roche Applied Bioscience) as per manufacturer protocol.</p></sec><sec id="s3-5"><title>Histology and immunohistochemistry</title><p>Paraffin embedding, sectioning and immunohistochemical analysis of zebrafish sections were performed as previously described (<xref ref-type="bibr" rid="bib3">Chen et al., 2014</xref>; <xref ref-type="bibr" rid="bib11">Ignatius et al., 2012</xref>). Anti-human SOX10 was performed at the MGH and BWH DF/HCC Research Pathology Cores. Slides were imaged using a transmitted light Olympus BX41 microscope and a Motic Easy Scan Pro slide scanner. Pathology review and staging were completed by board-certified sarcoma (G.P.N and E.Y.C) and hematology pathologist (R.P.H).</p></sec><sec id="s3-6"><title>Micro-injection and ERMS generation</title><p><italic>rag2:kRASG12D</italic> and <italic>rag2:GFP</italic> constructs were described previously (<xref ref-type="bibr" rid="bib19">Langenau et al., 2008</xref>; <xref ref-type="bibr" rid="bib18">Langenau et al., 2007</xref>). DNA plasmids were linearized with <italic>Xho1</italic>, phenol:chloroform-extracted, ethanol-precipitated, resuspended in 0.5 × Tris EDTA + 0.1 M KCl, and injected into one-cell CG1 strain embryos.</p></sec><sec id="s3-7"><title>FACS and tumor cell transplantation</title><p>FACS analysis and RMS cell transplantation were completed essentially as previously described (<xref ref-type="bibr" rid="bib3">Chen et al., 2014</xref>; <xref ref-type="bibr" rid="bib11">Ignatius et al., 2012</xref>; <xref ref-type="bibr" rid="bib18">Langenau et al., 2007</xref>; <xref ref-type="bibr" rid="bib38">Smith et al., 2010</xref>). <italic>tp53<sup>del/del</sup></italic> angiosarcomas, leukemias and ERMS tumor cells were stained with DAPI to exclude dead cells and sorted twice using a Laser BD FACSAria II Cell Sorter. Sort purity and viability were assessed after two rounds of sorting, exceeding 85% and 90%, respectively. GFP+ ERMS tumors were transplanted at limiting dilution and monitored for tumor engraftment under a fluorescent dissecting microscope from 10 to 90 days post-transplantation. Tumor-propagating cell frequency was quantified using the Extreme Limiting Dilution Analysis software package (<ext-link ext-link-type="uri" xlink:href="http://bioinf.wehi.edu.au/software/elda/">http://bioinf.wehi.edu.au/software/elda/</ext-link>). GFP+ tumor cells were isolated by FACS from a subset of transplanted fish and RNA isolated for RNA sequencing. Subsets of tumors were fixed in 4% PFA and embedded in paraffin blocks, sectioned and stained with Hematoxylin and Eosin. Sorted GFP+ <italic>tp53</italic> <sup>del/del</sup> leukemia cells were spun down onto a cytospin slide and processed by Wright/Giemsa staining.</p></sec><sec id="s3-8"><title>RNA sequencing and analysis</title><p>Paired-end reads from poly(A)<sup>+</sup> RNA-seq were aligned to the GRCz10 reference zebrafish genome with STAR v2.4.0 (<xref ref-type="bibr" rid="bib7">Dobin et al., 2013</xref>) using GRCz10v85 Ensembl annotations. PCR duplicates were removed with Picard v1.95 [http://broadinstitute.github.io/picard/] and reads aligning to ribosomal RNA were removed with RSeQC (<xref ref-type="bibr" rid="bib49">Wang et al., 2012</xref>) Gene counts were obtained from reads with an alignment quality of at least 10 using featureCounts (<xref ref-type="bibr" rid="bib23">Liao et al., 2014</xref>) and transformed to transcript per million (TPM) units. Human orthologues of zebrafish genes were obtained from the Beagle database (<xref ref-type="bibr" rid="bib43">Tang et al., 2017</xref>; available at: <ext-link ext-link-type="uri" xlink:href="http://chgr.mgh.harvard.edu/genomesrus/">http://chgr.mgh.harvard.edu/genomesrus/</ext-link>). Differential expression analysis was performed with DESeq2 (<xref ref-type="bibr" rid="bib24">Love et al., 2014</xref>), requiring log2(FC) ≥2 and an FDR &lt; 0.05 was required. Each tumor type was individually compared to the control samples. Clustering of differentially expressed genes used the partitioning around medoids (PAM) method in the cluster R package and the Pearson correlation was used as distance. The number of clusters was optimized with the <italic>silhouette</italic> function from the same <italic>cluster</italic> R package.</p></sec><sec id="s3-9"><title>Gene set enrichment analysis</title><p>Human tumor-specific gene signatures were assessed for enrichment in <italic>tp53<sup>del/del</sup></italic> tumor types using GSEA 3.0. (<xref ref-type="bibr" rid="bib29">Mootha et al., 2003</xref>; <xref ref-type="bibr" rid="bib40">Subramanian et al., 2005</xref>). Gene signatures were assessed for anigosarcoma (<xref ref-type="bibr" rid="bib1">Andersen et al., 2013</xref>), MPNST (<xref ref-type="bibr" rid="bib16">Kolberg et al., 2015</xref>), and ERMS (GEO:GSE108022). The ERMS signature was defined by genes up-regulated in both human and zebrafish <italic>kRAS<sup>G12D</sup></italic>-induced <italic>tp53<sup>wt/wt</sup></italic> ERMS when compared with normal muscle (log2(FC) ≥2). GSEA was completed in comparing individual tumor types to all other tumors using the default parameters and 1000 permutations of the data.</p></sec><sec id="s3-10"><title>Comparison of <italic>tp53<sup>del/del</sup></italic> and <italic>tp53<sup>M214K/M214K</sup></italic> MPNST</title><p>RNA sequencing data from four <italic>tp53<sup>M214K/M214K</sup></italic> homozygous mutant MPNST samples were processed as described above. Differential expression analysis was performed as described above, comparing <italic>tp53<sup>del/del</sup></italic> and <italic>tp53<sup>M214K/M214K</sup></italic> MPNSTs to whole CG1 controls. Statistical significance was assessed with a one-sided Fisher’s exact test on a background of genes that were expressed in at least 4 out of 15 samples.</p></sec><sec id="s3-11"><title>Molecular signature database (MSigDB) analysis and leukemia similarities with NK cells</title><p>The top 500 most differentially regulated genes within each tumor type were identified and assigned human gene IDs using the Beagle database. These humanized gene lists were then queried for overlaps with molecular signatures from MSigDB. Only the top 50 enriched gene sets were analyzed and representative examples of enriched data sets are shown in <xref ref-type="fig" rid="fig3">Figure 3C</xref>. For blood cell analysis in <xref ref-type="fig" rid="fig3">Figure 3D,a</xref> 30 gene signature was defined for each of the major blood cell lineages and then cumulative gene expression analyzed across tumor types as described by <xref ref-type="bibr" rid="bib43">Tang et al. (2017)</xref>. The top 200 genes up-regulated in <italic>tp53<sup>del/del</sup></italic> leukemias compared to all other tumors where assessed relative to gene sets generated using SMARTseq as described in <xref ref-type="bibr" rid="bib43">Tang et al. (2017)</xref>.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank Dr. Jim Amatruda for sharing zebrafish MPNST RNAseq sample data.</p></ack><sec id="s4" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Writing—original draft, Writing—review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis, Investigation, Writing—original draft, Writing—review and editing</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Data curation, Formal analysis, Investigation, Writing—review and editing</p></fn><fn fn-type="con" id="con4"><p>Data curation, Formal analysis, Investigation, Writing—review and editing</p></fn><fn fn-type="con" id="con5"><p>Formal analysis, Writing—review and editing</p></fn><fn fn-type="con" id="con6"><p>Resources, Methodology, Writing—review and editing</p></fn><fn fn-type="con" id="con7"><p>Formal analysis, Investigation, Methodology, Writing—review and editing</p></fn><fn fn-type="con" id="con8"><p>Resources</p></fn><fn fn-type="con" id="con9"><p>Formal analysis</p></fn><fn fn-type="con" id="con10"><p>Investigation</p></fn><fn fn-type="con" id="con11"><p>Data curation</p></fn><fn fn-type="con" id="con12"><p>Resources</p></fn><fn fn-type="con" id="con13"><p>Formal analysis, Writing—review and editing</p></fn><fn fn-type="con" id="con14"><p>Formal analysis</p></fn><fn fn-type="con" id="con15"><p>Formal analysis, Writing—review and editing</p></fn><fn fn-type="con" id="con16"><p>Data curation</p></fn><fn fn-type="con" id="con17"><p>Resources, Methodology, Writing—review and editing</p></fn><fn fn-type="con" id="con18"><p>Supervision, Funding acquisition, Writing—original draft, Writing—review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: Animal studies were approved by the Massachusetts General Hospital Subcommittee on Research Animal Care under the protocol #2011-N-000127</p></fn></fn-group></sec><sec id="s5" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><object-id pub-id-type="doi">10.7554/eLife.37202.021</object-id><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-37202-transrepform-v1.docx"/></supplementary-material><sec id="s6" sec-type="data-availability"><title>Data availability</title><p>Sequencing data has been deposited in GEO under accession code GSE109581</p><p>The following dataset was generated:</p><p><related-object content-type="generated-dataset" id="dataset1" source-id="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE109581" source-id-type="uri"><collab collab-type="author">Myron S Ignatius</collab><collab collab-type="author">Madeline N Hayes</collab><collab collab-type="author">David M Langenau</collab><year>2018</year><source>tp53 deficiency causes a wide tumor spectrum and increases embryonal rhabdomyosarcoma metastasis in zebrafish</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE109581">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE109581</ext-link><comment>Publicly available at the NCBI Gene Expression Omnibus (accession no. GSE109581)</comment></related-object></p><p>The following previously published datasets were used:</p><p><related-object content-type="generated-dataset" id="dataset2" source-id="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE100911" source-id-type="uri"><collab collab-type="author">Qin Tang</collab><collab collab-type="author">David M Langenau</collab><year>2017</year><source>Dissecting hematopoietic and renal cell heterogeneity in adult zebrafish at single cell resolution using RNA sequencing [Smart-seq]</source><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE100911">http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE100911</ext-link><comment>Publicly available at the NCBI Gene Expression Omnibus (accession no. GSE100911)</comment></related-object></p><p><related-object content-type="generated-dataset" id="dataset3" source-id="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE100910" source-id-type="uri"><collab collab-type="author">Qin Tang</collab><collab collab-type="author">David M Langenau</collab><year>2017</year><source>Dissecting hematopoietic and renal cell heterogeneity in adult zebrafish at single cell resolution using RNA sequencing [inDrops]</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE100910">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE100910</ext-link><comment>Publicly available at the NCBI Gene Expression Omnibus (accession no. GSE100910)</comment></related-object></p><p><related-object content-type="generated-dataset" id="dataset4" source-id="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE100912" source-id-type="uri"><collab collab-type="author">Qin Tang</collab><collab collab-type="author">David M Langenau</collab><year>2017</year><source>Dissecting hematopoietic and renal cell heterogeneity in adult zebrafish at single cell resolution using RNA sequencing [bulk RNA-seq]</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE100912">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE100912</ext-link><comment>Publicly available at the NCBI Gene Expression Omnibus (accession no. GSE100912)</comment></related-object></p></sec></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersen</surname> <given-names>NJ</given-names></name><name><surname>Nickoloff</surname> <given-names>BJ</given-names></name><name><surname>Dykema</surname> <given-names>KJ</given-names></name><name><surname>Boguslawski</surname> <given-names>EA</given-names></name><name><surname>Krivochenitser</surname> <given-names>RI</given-names></name><name><surname>Froman</surname> <given-names>RE</given-names></name><name><surname>Dawes</surname> <given-names>MJ</given-names></name><name><surname>Baker</surname> <given-names>LH</given-names></name><name><surname>Thomas</surname> <given-names>DG</given-names></name><name><surname>Kamstock</surname> <given-names>DA</given-names></name><name><surname>Kitchell</surname> <given-names>BE</given-names></name><name><surname>Furge</surname> <given-names>KA</given-names></name><name><surname>Duesbery</surname> <given-names>NS</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Pharmacologic inhibition of MEK signaling prevents growth of canine hemangiosarcoma</article-title><source>Molecular Cancer Therapeutics</source><volume>12</volume><fpage>1701</fpage><lpage>1714</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-12-0893</pub-id><pub-id pub-id-type="pmid">23804705</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berghmans</surname> <given-names>S</given-names></name><name><surname>Murphey</surname> <given-names>RD</given-names></name><name><surname>Wienholds</surname> <given-names>E</given-names></name><name><surname>Neuberg</surname> <given-names>D</given-names></name><name><surname>Kutok</surname> <given-names>JL</given-names></name><name><surname>Fletcher</surname> <given-names>CD</given-names></name><name><surname>Morris</surname> <given-names>JP</given-names></name><name><surname>Liu</surname> <given-names>TX</given-names></name><name><surname>Schulte-Merker</surname> <given-names>S</given-names></name><name><surname>Kanki</surname> <given-names>JP</given-names></name><name><surname>Plasterk</surname> <given-names>R</given-names></name><name><surname>Zon</surname> <given-names>LI</given-names></name><name><surname>Look</surname> <given-names>AT</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>tp53 mutant zebrafish develop malignant peripheral nerve sheath tumors</article-title><source>PNAS</source><volume>102</volume><fpage>407</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1073/pnas.0406252102</pub-id><pub-id pub-id-type="pmid">15630097</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>EY</given-names></name><name><surname>DeRan</surname> <given-names>MT</given-names></name><name><surname>Ignatius</surname> <given-names>MS</given-names></name><name><surname>Grandinetti</surname> <given-names>KB</given-names></name><name><surname>Clagg</surname> <given-names>R</given-names></name><name><surname>McCarthy</surname> <given-names>KM</given-names></name><name><surname>Lobbardi</surname> <given-names>RM</given-names></name><name><surname>Brockmann</surname> <given-names>J</given-names></name><name><surname>Keller</surname> <given-names>C</given-names></name><name><surname>Wu</surname> <given-names>X</given-names></name><name><surname>Langenau</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Glycogen synthase kinase 3 inhibitors induce the canonical WNT/β-catenin pathway to suppress growth and self-renewal in embryonal Rhabdomyosarcoma</article-title><source>PNAS</source><volume>111</volume><fpage>5349</fpage><lpage>5354</lpage><pub-id pub-id-type="doi">10.1073/pnas.1317731111</pub-id><pub-id pub-id-type="pmid">24706870</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>X</given-names></name><name><surname>Stewart</surname> <given-names>E</given-names></name><name><surname>Shelat</surname> <given-names>AA</given-names></name><name><surname>Qu</surname> <given-names>C</given-names></name><name><surname>Bahrami</surname> <given-names>A</given-names></name><name><surname>Hatley</surname> <given-names>M</given-names></name><name><surname>Wu</surname> <given-names>G</given-names></name><name><surname>Bradley</surname> <given-names>C</given-names></name><name><surname>McEvoy</surname> <given-names>J</given-names></name><name><surname>Pappo</surname> <given-names>A</given-names></name><name><surname>Spunt</surname> <given-names>S</given-names></name><name><surname>Valentine</surname> <given-names>MB</given-names></name><name><surname>Valentine</surname> <given-names>V</given-names></name><name><surname>Krafcik</surname> <given-names>F</given-names></name><name><surname>Lang</surname> <given-names>WH</given-names></name><name><surname>Wierdl</surname> <given-names>M</given-names></name><name><surname>Tsurkan</surname> <given-names>L</given-names></name><name><surname>Tolleman</surname> <given-names>V</given-names></name><name><surname>Federico</surname> <given-names>SM</given-names></name><name><surname>Morton</surname> <given-names>C</given-names></name><name><surname>Lu</surname> <given-names>C</given-names></name><name><surname>Ding</surname> <given-names>L</given-names></name><name><surname>Easton</surname> <given-names>J</given-names></name><name><surname>Rusch</surname> <given-names>M</given-names></name><name><surname>Nagahawatte</surname> <given-names>P</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Parker</surname> <given-names>M</given-names></name><name><surname>Wei</surname> <given-names>L</given-names></name><name><surname>Hedlund</surname> <given-names>E</given-names></name><name><surname>Finkelstein</surname> <given-names>D</given-names></name><name><surname>Edmonson</surname> <given-names>M</given-names></name><name><surname>Shurtleff</surname> <given-names>S</given-names></name><name><surname>Boggs</surname> <given-names>K</given-names></name><name><surname>Mulder</surname> <given-names>H</given-names></name><name><surname>Yergeau</surname> <given-names>D</given-names></name><name><surname>Skapek</surname> <given-names>S</given-names></name><name><surname>Hawkins</surname> <given-names>DS</given-names></name><name><surname>Ramirez</surname> <given-names>N</given-names></name><name><surname>Potter</surname> <given-names>PM</given-names></name><name><surname>Sandoval</surname> <given-names>JA</given-names></name><name><surname>Davidoff</surname> <given-names>AM</given-names></name><name><surname>Mardis</surname> <given-names>ER</given-names></name><name><surname>Wilson</surname> <given-names>RK</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Downing</surname> <given-names>JR</given-names></name><name><surname>Dyer</surname> <given-names>MA</given-names></name><collab>St. Jude Children’s Research Hospital–Washington University Pediatric Cancer Genome Project</collab></person-group><year iso-8601-date="2013">2013</year><article-title>Targeting oxidative stress in embryonal Rhabdomyosarcoma</article-title><source>Cancer Cell</source><volume>24</volume><fpage>710</fpage><lpage>724</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2013.11.002</pub-id><pub-id pub-id-type="pmid">24332040</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choorapoikayil</surname> <given-names>S</given-names></name><name><surname>Kuiper</surname> <given-names>RV</given-names></name><name><surname>de Bruin</surname> <given-names>A</given-names></name><name><surname>den Hertog</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Haploinsufficiency of the genes encoding the tumor suppressor pten predisposes zebrafish to hemangiosarcoma</article-title><source>Disease Models &amp; Mechanisms</source><volume>5</volume><fpage>241</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1242/dmm.008326</pub-id><pub-id pub-id-type="pmid">22071262</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cicalese</surname> <given-names>A</given-names></name><name><surname>Bonizzi</surname> <given-names>G</given-names></name><name><surname>Pasi</surname> <given-names>CE</given-names></name><name><surname>Faretta</surname> <given-names>M</given-names></name><name><surname>Ronzoni</surname> <given-names>S</given-names></name><name><surname>Giulini</surname> <given-names>B</given-names></name><name><surname>Brisken</surname> <given-names>C</given-names></name><name><surname>Minucci</surname> <given-names>S</given-names></name><name><surname>Di Fiore</surname> <given-names>PP</given-names></name><name><surname>Pelicci</surname> <given-names>PG</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells</article-title><source>Cell</source><volume>138</volume><fpage>1083</fpage><lpage>1095</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.06.048</pub-id><pub-id pub-id-type="pmid">19766563</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobin</surname> <given-names>A</given-names></name><name><surname>Davis</surname> <given-names>CA</given-names></name><name><surname>Schlesinger</surname> <given-names>F</given-names></name><name><surname>Drenkow</surname> <given-names>J</given-names></name><name><surname>Zaleski</surname> <given-names>C</given-names></name><name><surname>Jha</surname> <given-names>S</given-names></name><name><surname>Batut</surname> <given-names>P</given-names></name><name><surname>Chaisson</surname> <given-names>M</given-names></name><name><surname>Gingeras</surname> <given-names>TR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>STAR: ultrafast universal RNA-seq aligner</article-title><source>Bioinformatics</source><volume>29</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts635</pub-id><pub-id pub-id-type="pmid">23104886</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donehower</surname> <given-names>LA</given-names></name><name><surname>Harvey</surname> <given-names>M</given-names></name><name><surname>Slagle</surname> <given-names>BL</given-names></name><name><surname>McArthur</surname> <given-names>MJ</given-names></name><name><surname>Montgomery</surname> <given-names>CA</given-names></name><name><surname>Butel</surname> <given-names>JS</given-names></name><name><surname>Bradley</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours</article-title><source>Nature</source><volume>356</volume><fpage>215</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1038/356215a0</pub-id><pub-id pub-id-type="pmid">1552940</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harvey</surname> <given-names>M</given-names></name><name><surname>McArthur</surname> <given-names>MJ</given-names></name><name><surname>Montgomery</surname> <given-names>CA</given-names></name><name><surname>Butel</surname> <given-names>JS</given-names></name><name><surname>Bradley</surname> <given-names>A</given-names></name><name><surname>Donehower</surname> <given-names>LA</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice</article-title><source>Nature Genetics</source><volume>5</volume><fpage>225</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1038/ng1193-225</pub-id><pub-id pub-id-type="pmid">8275085</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayes</surname> <given-names>MN</given-names></name><name><surname>McCarthy</surname> <given-names>KM</given-names></name><name><surname>Jin</surname> <given-names>A</given-names></name><name><surname>Oliveira</surname> <given-names>ML</given-names></name><name><surname>Iyer</surname> <given-names>S</given-names></name><name><surname>Garcia</surname> <given-names>SP</given-names></name><name><surname>Sindiri</surname> <given-names>S</given-names></name><name><surname>Gryder</surname> <given-names>B</given-names></name><name><surname>Motala</surname> <given-names>Z</given-names></name><name><surname>Nielsen</surname> <given-names>GP</given-names></name><name><surname>Borg</surname> <given-names>J-P</given-names></name><name><surname>van de Rijn</surname> <given-names>M</given-names></name><name><surname>Malkin</surname> <given-names>D</given-names></name><name><surname>Khan</surname> <given-names>J</given-names></name><name><surname>Ignatius</surname> <given-names>MS</given-names></name><name><surname>Langenau</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Vangl2 regulates stem cell self-renewal programs and growth in Rhabdomyosarcoma through a wnt/PCP/RhoA signaling Axis</article-title><source>Cell Stem Cell</source><volume>22</volume><fpage>414</fpage><lpage>427</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2018.02.002</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ignatius</surname> <given-names>MS</given-names></name><name><surname>Chen</surname> <given-names>E</given-names></name><name><surname>Elpek</surname> <given-names>NM</given-names></name><name><surname>Fuller</surname> <given-names>AZ</given-names></name><name><surname>Tenente</surname> <given-names>IM</given-names></name><name><surname>Clagg</surname> <given-names>R</given-names></name><name><surname>Liu</surname> <given-names>S</given-names></name><name><surname>Blackburn</surname> <given-names>JS</given-names></name><name><surname>Linardic</surname> <given-names>CM</given-names></name><name><surname>Rosenberg</surname> <given-names>AE</given-names></name><name><surname>Nielsen</surname> <given-names>PG</given-names></name><name><surname>Mempel</surname> <given-names>TR</given-names></name><name><surname>Langenau</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>In vivo imaging of tumor-propagating cells, regional tumor heterogeneity, and dynamic cell movements in embryonal Rhabdomyosarcoma</article-title><source>Cancer Cell</source><volume>21</volume><fpage>680</fpage><lpage>693</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2012.03.043</pub-id><pub-id pub-id-type="pmid">22624717</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ignatius</surname> <given-names>MS</given-names></name><name><surname>Hayes</surname> <given-names>MN</given-names></name><name><surname>Lobbardi</surname> <given-names>R</given-names></name><name><surname>Chen</surname> <given-names>EY</given-names></name><name><surname>McCarthy</surname> <given-names>KM</given-names></name><name><surname>Sreenivas</surname> <given-names>P</given-names></name><name><surname>Motala</surname> <given-names>Z</given-names></name><name><surname>Durbin</surname> <given-names>AD</given-names></name><name><surname>Molodtsov</surname> <given-names>A</given-names></name><name><surname>Reeder</surname> <given-names>S</given-names></name><name><surname>Jin</surname> <given-names>A</given-names></name><name><surname>Sindiri</surname> <given-names>S</given-names></name><name><surname>Beleyea</surname> <given-names>BC</given-names></name><name><surname>Bhere</surname> <given-names>D</given-names></name><name><surname>Alexander</surname> <given-names>MS</given-names></name><name><surname>Shah</surname> <given-names>K</given-names></name><name><surname>Keller</surname> <given-names>C</given-names></name><name><surname>Linardic</surname> <given-names>CM</given-names></name><name><surname>Nielsen</surname> <given-names>PG</given-names></name><name><surname>Malkin</surname> <given-names>D</given-names></name><name><surname>Khan</surname> <given-names>J</given-names></name><name><surname>Langenau</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The NOTCH1/SNAIL1/MEF2C pathway regulates growth and Self-Renewal in embryonal Rhabdomyosarcoma</article-title><source>Cell Reports</source><volume>19</volume><fpage>2304</fpage><lpage>2318</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2017.05.061</pub-id><pub-id pub-id-type="pmid">28614716</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacks</surname> <given-names>T</given-names></name><name><surname>Remington</surname> <given-names>L</given-names></name><name><surname>Williams</surname> <given-names>BO</given-names></name><name><surname>Schmitt</surname> <given-names>EM</given-names></name><name><surname>Halachmi</surname> <given-names>S</given-names></name><name><surname>Bronson</surname> <given-names>RT</given-names></name><name><surname>Weinberg</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Tumor spectrum analysis in p53-mutant mice</article-title><source>Current Biology</source><volume>4</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/S0960-9822(00)00002-6</pub-id><pub-id pub-id-type="pmid">7922305</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kastenhuber</surname> <given-names>ER</given-names></name><name><surname>Lowe</surname> <given-names>SW</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Putting p53 in Context</article-title><source>Cell</source><volume>170</volume><fpage>1062</fpage><lpage>1078</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.08.028</pub-id><pub-id pub-id-type="pmid">28886379</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawakami</surname> <given-names>K</given-names></name><name><surname>Shima</surname> <given-names>A</given-names></name><name><surname>Kawakami</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Identification of a functional transposase of the Tol2 element, an Ac-like element from the japanese medaka fish, and its transposition in the zebrafish germ lineage</article-title><source>PNAS</source><volume>97</volume><fpage>11403</fpage><lpage>11408</lpage><pub-id pub-id-type="doi">10.1073/pnas.97.21.11403</pub-id><pub-id pub-id-type="pmid">11027340</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolberg</surname> <given-names>M</given-names></name><name><surname>Høland</surname> <given-names>M</given-names></name><name><surname>Lind</surname> <given-names>GE</given-names></name><name><surname>Ågesen</surname> <given-names>TH</given-names></name><name><surname>Skotheim</surname> <given-names>RI</given-names></name><name><surname>Hall</surname> <given-names>KS</given-names></name><name><surname>Mandahl</surname> <given-names>N</given-names></name><name><surname>Smeland</surname> <given-names>S</given-names></name><name><surname>Mertens</surname> <given-names>F</given-names></name><name><surname>Davidson</surname> <given-names>B</given-names></name><name><surname>Lothe</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Protein expression of BIRC5, TK1, and TOP2A in malignant peripheral nerve sheath tumours--A prognostic test after surgical resection</article-title><source>Molecular Oncology</source><volume>9</volume><fpage>1129</fpage><lpage>1139</lpage><pub-id pub-id-type="doi">10.1016/j.molonc.2015.02.005</pub-id><pub-id pub-id-type="pmid">25769404</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lang</surname> <given-names>GA</given-names></name><name><surname>Iwakuma</surname> <given-names>T</given-names></name><name><surname>Suh</surname> <given-names>YA</given-names></name><name><surname>Liu</surname> <given-names>G</given-names></name><name><surname>Rao</surname> <given-names>VA</given-names></name><name><surname>Parant</surname> <given-names>JM</given-names></name><name><surname>Valentin-Vega</surname> <given-names>YA</given-names></name><name><surname>Terzian</surname> <given-names>T</given-names></name><name><surname>Caldwell</surname> <given-names>LC</given-names></name><name><surname>Strong</surname> <given-names>LC</given-names></name><name><surname>El-Naggar</surname> <given-names>AK</given-names></name><name><surname>Lozano</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome</article-title><source>Cell</source><volume>119</volume><fpage>861</fpage><lpage>872</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2004.11.006</pub-id><pub-id pub-id-type="pmid">15607981</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langenau</surname> <given-names>DM</given-names></name><name><surname>Keefe</surname> <given-names>MD</given-names></name><name><surname>Storer</surname> <given-names>NY</given-names></name><name><surname>Guyon</surname> <given-names>JR</given-names></name><name><surname>Kutok</surname> <given-names>JL</given-names></name><name><surname>Le</surname> <given-names>X</given-names></name><name><surname>Goessling</surname> <given-names>W</given-names></name><name><surname>Neuberg</surname> <given-names>DS</given-names></name><name><surname>Kunkel</surname> <given-names>LM</given-names></name><name><surname>Zon</surname> <given-names>LI</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Effects of RAS on the genesis of embryonal Rhabdomyosarcoma</article-title><source>Genes &amp; Development</source><volume>21</volume><fpage>1382</fpage><lpage>1395</lpage><pub-id pub-id-type="doi">10.1101/gad.1545007</pub-id><pub-id pub-id-type="pmid">17510286</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langenau</surname> <given-names>DM</given-names></name><name><surname>Keefe</surname> <given-names>MD</given-names></name><name><surname>Storer</surname> <given-names>NY</given-names></name><name><surname>Jette</surname> <given-names>CA</given-names></name><name><surname>Smith</surname> <given-names>AC</given-names></name><name><surname>Ceol</surname> <given-names>CJ</given-names></name><name><surname>Bourque</surname> <given-names>C</given-names></name><name><surname>Look</surname> <given-names>AT</given-names></name><name><surname>Zon</surname> <given-names>LI</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Co-injection strategies to modify radiation sensitivity and tumor initiation in transgenic zebrafish</article-title><source>Oncogene</source><volume>27</volume><fpage>4242</fpage><lpage>4248</lpage><pub-id pub-id-type="doi">10.1038/onc.2008.56</pub-id><pub-id pub-id-type="pmid">18345029</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lavigueur</surname> <given-names>A</given-names></name><name><surname>Maltby</surname> <given-names>V</given-names></name><name><surname>Mock</surname> <given-names>D</given-names></name><name><surname>Rossant</surname> <given-names>J</given-names></name><name><surname>Pawson</surname> <given-names>T</given-names></name><name><surname>Bernstein</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="1989">1989</year><article-title>High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene</article-title><source>Molecular and Cellular Biology</source><volume>9</volume><fpage>3982</fpage><lpage>3991</lpage><pub-id pub-id-type="doi">10.1128/MCB.9.9.3982</pub-id><pub-id pub-id-type="pmid">2476668</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>JM</given-names></name><name><surname>Abrahamson</surname> <given-names>JL</given-names></name><name><surname>Kandel</surname> <given-names>R</given-names></name><name><surname>Donehower</surname> <given-names>LA</given-names></name><name><surname>Bernstein</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Susceptibility to radiation-carcinogenesis and accumulation of chromosomal breakage in p53 deficient mice</article-title><source>Oncogene</source><volume>9</volume><fpage>3731</fpage><lpage>3736</lpage><pub-id pub-id-type="pmid">7970733</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname> <given-names>X</given-names></name><name><surname>Graham</surname> <given-names>DK</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Natural killer cell neoplasms</article-title><source>Cancer</source><volume>112</volume><fpage>1425</fpage><lpage>1436</lpage><pub-id pub-id-type="doi">10.1002/cncr.23316</pub-id><pub-id pub-id-type="pmid">18286525</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname> <given-names>Y</given-names></name><name><surname>Smyth</surname> <given-names>GK</given-names></name><name><surname>Shi</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>featureCounts: an efficient general purpose program for assigning sequence reads to genomic features</article-title><source>Bioinformatics</source><volume>30</volume><fpage>923</fpage><lpage>930</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btt656</pub-id><pub-id pub-id-type="pmid">24227677</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname> <given-names>MI</given-names></name><name><surname>Huber</surname> <given-names>W</given-names></name><name><surname>Anders</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title><source>Genome Biology</source><volume>15</volume><elocation-id>550</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmid">25516281</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname> <given-names>AC</given-names></name><name><surname>Lee</surname> <given-names>HB</given-names></name><name><surname>Clark</surname> <given-names>KJ</given-names></name><name><surname>Ekker</surname> <given-names>SC</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>High efficiency in vivo genome engineering with a simplified 15-RVD GoldyTALEN design</article-title><source>PloS One</source><volume>8</volume><elocation-id>e65259</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0065259</pub-id><pub-id pub-id-type="pmid">23734242</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malkin</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Li-fraumeni syndrome</article-title><source>Genes &amp; Cancer</source><volume>2</volume><fpage>475</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.1177/1947601911413466</pub-id><pub-id pub-id-type="pmid">21779515</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meletis</surname> <given-names>K</given-names></name><name><surname>Wirta</surname> <given-names>V</given-names></name><name><surname>Hede</surname> <given-names>SM</given-names></name><name><surname>Nistér</surname> <given-names>M</given-names></name><name><surname>Lundeberg</surname> <given-names>J</given-names></name><name><surname>Frisén</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>p53 suppresses the self-renewal of adult neural stem cells</article-title><source>Development</source><volume>133</volume><fpage>363</fpage><lpage>369</lpage><pub-id pub-id-type="doi">10.1242/dev.02208</pub-id><pub-id pub-id-type="pmid">16368933</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mizgireuv</surname> <given-names>IV</given-names></name><name><surname>Revskoy</surname> <given-names>SY</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Transplantable tumor lines generated in clonal zebrafish</article-title><source>Cancer Research</source><volume>66</volume><fpage>3120</fpage><lpage>3125</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-3800</pub-id><pub-id pub-id-type="pmid">16540662</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mootha</surname> <given-names>VK</given-names></name><name><surname>Lindgren</surname> <given-names>CM</given-names></name><name><surname>Eriksson</surname> <given-names>K-F</given-names></name><name><surname>Subramanian</surname> <given-names>A</given-names></name><name><surname>Sihag</surname> <given-names>S</given-names></name><name><surname>Lehar</surname> <given-names>J</given-names></name><name><surname>Puigserver</surname> <given-names>P</given-names></name><name><surname>Carlsson</surname> <given-names>E</given-names></name><name><surname>Ridderstråle</surname> <given-names>M</given-names></name><name><surname>Laurila</surname> <given-names>E</given-names></name><name><surname>Houstis</surname> <given-names>N</given-names></name><name><surname>Daly</surname> <given-names>MJ</given-names></name><name><surname>Patterson</surname> <given-names>N</given-names></name><name><surname>Mesirov</surname> <given-names>JP</given-names></name><name><surname>Golub</surname> <given-names>TR</given-names></name><name><surname>Tamayo</surname> <given-names>P</given-names></name><name><surname>Spiegelman</surname> <given-names>B</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name><name><surname>Hirschhorn</surname> <given-names>JN</given-names></name><name><surname>Altshuler</surname> <given-names>D</given-names></name><name><surname>Groop</surname> <given-names>LC</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes</article-title><source>Nature Genetics</source><volume>34</volume><fpage>267</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1038/ng1180</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mosimann</surname> <given-names>C</given-names></name><name><surname>Kaufman</surname> <given-names>CK</given-names></name><name><surname>Li</surname> <given-names>P</given-names></name><name><surname>Pugach</surname> <given-names>EK</given-names></name><name><surname>Tamplin</surname> <given-names>OJ</given-names></name><name><surname>Zon</surname> <given-names>LI</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Ubiquitous transgene expression and Cre-based recombination driven by the ubiquitin promoter in zebrafish</article-title><source>Development</source><volume>138</volume><fpage>169</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1242/dev.059345</pub-id><pub-id pub-id-type="pmid">21138979</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muller</surname> <given-names>PA</given-names></name><name><surname>Vousden</surname> <given-names>KH</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Mutant p53 in Cancer: new functions and therapeutic opportunities</article-title><source>Cancer Cell</source><volume>25</volume><fpage>304</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2014.01.021</pub-id><pub-id pub-id-type="pmid">24651012</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neff</surname> <given-names>KL</given-names></name><name><surname>Argue</surname> <given-names>DP</given-names></name><name><surname>Ma</surname> <given-names>AC</given-names></name><name><surname>Lee</surname> <given-names>HB</given-names></name><name><surname>Clark</surname> <given-names>KJ</given-names></name><name><surname>Ekker</surname> <given-names>SC</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Mojo hand, a TALEN design tool for genome editing applications</article-title><source>BMC Bioinformatics</source><volume>14</volume><elocation-id>1</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2105-14-1</pub-id><pub-id pub-id-type="pmid">23323762</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neumann</surname> <given-names>JC</given-names></name><name><surname>Lillard</surname> <given-names>K</given-names></name><name><surname>Damoulis</surname> <given-names>V</given-names></name><name><surname>Amatruda</surname> <given-names>JF</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Zebrafish models of germ cell tumor</article-title><source>Methods in Cell Biology</source><volume>105</volume><fpage>1</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-381320-6.00001-1</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olive</surname> <given-names>KP</given-names></name><name><surname>Tuveson</surname> <given-names>DA</given-names></name><name><surname>Ruhe</surname> <given-names>ZC</given-names></name><name><surname>Yin</surname> <given-names>B</given-names></name><name><surname>Willis</surname> <given-names>NA</given-names></name><name><surname>Bronson</surname> <given-names>RT</given-names></name><name><surname>Crowley</surname> <given-names>D</given-names></name><name><surname>Jacks</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome</article-title><source>Cell</source><volume>119</volume><fpage>847</fpage><lpage>860</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2004.11.004</pub-id><pub-id pub-id-type="pmid">15607980</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parant</surname> <given-names>JM</given-names></name><name><surname>George</surname> <given-names>SA</given-names></name><name><surname>Holden</surname> <given-names>JA</given-names></name><name><surname>Yost</surname> <given-names>HJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Genetic modeling of Li-Fraumeni syndrome in zebrafish</article-title><source>Disease Models &amp; Mechanisms</source><volume>3</volume><fpage>45</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1242/dmm.003749</pub-id><pub-id pub-id-type="pmid">20075382</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seki</surname> <given-names>M</given-names></name><name><surname>Nishimura</surname> <given-names>R</given-names></name><name><surname>Yoshida</surname> <given-names>K</given-names></name><name><surname>Shimamura</surname> <given-names>T</given-names></name><name><surname>Shiraishi</surname> <given-names>Y</given-names></name><name><surname>Sato</surname> <given-names>Y</given-names></name><name><surname>Kato</surname> <given-names>M</given-names></name><name><surname>Chiba</surname> <given-names>K</given-names></name><name><surname>Tanaka</surname> <given-names>H</given-names></name><name><surname>Hoshino</surname> <given-names>N</given-names></name><name><surname>Nagae</surname> <given-names>G</given-names></name><name><surname>Shiozawa</surname> <given-names>Y</given-names></name><name><surname>Okuno</surname> <given-names>Y</given-names></name><name><surname>Hosoi</surname> <given-names>H</given-names></name><name><surname>Tanaka</surname> <given-names>Y</given-names></name><name><surname>Okita</surname> <given-names>H</given-names></name><name><surname>Miyachi</surname> <given-names>M</given-names></name><name><surname>Souzaki</surname> <given-names>R</given-names></name><name><surname>Taguchi</surname> <given-names>T</given-names></name><name><surname>Koh</surname> <given-names>K</given-names></name><name><surname>Hanada</surname> <given-names>R</given-names></name><name><surname>Kato</surname> <given-names>K</given-names></name><name><surname>Nomura</surname> <given-names>Y</given-names></name><name><surname>Akiyama</surname> <given-names>M</given-names></name><name><surname>Oka</surname> <given-names>A</given-names></name><name><surname>Igarashi</surname> <given-names>T</given-names></name><name><surname>Miyano</surname> <given-names>S</given-names></name><name><surname>Aburatani</surname> <given-names>H</given-names></name><name><surname>Hayashi</surname> <given-names>Y</given-names></name><name><surname>Ogawa</surname> <given-names>S</given-names></name><name><surname>Takita</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Integrated genetic and epigenetic analysis defines novel molecular subgroups in Rhabdomyosarcoma</article-title><source>Nature Communications</source><volume>6</volume><elocation-id>8557</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms8557</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname> <given-names>J</given-names></name><name><surname>Padmanabhan</surname> <given-names>A</given-names></name><name><surname>de Groh</surname> <given-names>ED</given-names></name><name><surname>Lee</surname> <given-names>JS</given-names></name><name><surname>Haidar</surname> <given-names>S</given-names></name><name><surname>Dahlberg</surname> <given-names>S</given-names></name><name><surname>Guo</surname> <given-names>F</given-names></name><name><surname>He</surname> <given-names>S</given-names></name><name><surname>Wolman</surname> <given-names>MA</given-names></name><name><surname>Granato</surname> <given-names>M</given-names></name><name><surname>Lawson</surname> <given-names>ND</given-names></name><name><surname>Wolfe</surname> <given-names>SA</given-names></name><name><surname>Kim</surname> <given-names>SH</given-names></name><name><surname>Solnica-Krezel</surname> <given-names>L</given-names></name><name><surname>Kanki</surname> <given-names>JP</given-names></name><name><surname>Ligon</surname> <given-names>KL</given-names></name><name><surname>Epstein</surname> <given-names>JA</given-names></name><name><surname>Look</surname> <given-names>AT</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Zebrafish neurofibromatosis type 1 genes have redundant functions in tumorigenesis and embryonic development</article-title><source>Disease Models &amp; Mechanisms</source><volume>5</volume><fpage>881</fpage><lpage>894</lpage><pub-id pub-id-type="doi">10.1242/dmm.009779</pub-id><pub-id pub-id-type="pmid">22773753</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname> <given-names>AC</given-names></name><name><surname>Raimondi</surname> <given-names>AR</given-names></name><name><surname>Salthouse</surname> <given-names>CD</given-names></name><name><surname>Ignatius</surname> <given-names>MS</given-names></name><name><surname>Blackburn</surname> <given-names>JS</given-names></name><name><surname>Mizgirev</surname> <given-names>IV</given-names></name><name><surname>Storer</surname> <given-names>NY</given-names></name><name><surname>de Jong</surname> <given-names>JL</given-names></name><name><surname>Chen</surname> <given-names>AT</given-names></name><name><surname>Zhou</surname> <given-names>Y</given-names></name><name><surname>Revskoy</surname> <given-names>S</given-names></name><name><surname>Zon</surname> <given-names>LI</given-names></name><name><surname>Langenau</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>High-throughput cell transplantation establishes that tumor-initiating cells are abundant in zebrafish T-cell acute lymphoblastic leukemia</article-title><source>Blood</source><volume>115</volume><fpage>3296</fpage><lpage>3303</lpage><pub-id pub-id-type="doi">10.1182/blood-2009-10-246488</pub-id><pub-id pub-id-type="pmid">20056790</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soliman</surname> <given-names>DS</given-names></name><name><surname>Sabbagh</surname> <given-names>AA</given-names></name><name><surname>Omri</surname> <given-names>HE</given-names></name><name><surname>Ibrahim</surname> <given-names>FA</given-names></name><name><surname>Amer</surname> <given-names>AM</given-names></name><name><surname>Otazu</surname> <given-names>IB</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Rare aggressive natural killer cell leukemia presented with bone marrow fibrosis - a diagnostic challenge</article-title><source>SpringerPlus</source><volume>3</volume><elocation-id>390</elocation-id><pub-id pub-id-type="doi">10.1186/2193-1801-3-390</pub-id><pub-id pub-id-type="pmid">25126488</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname> <given-names>A</given-names></name><name><surname>Tamayo</surname> <given-names>P</given-names></name><name><surname>Mootha</surname> <given-names>VK</given-names></name><name><surname>Mukherjee</surname> <given-names>S</given-names></name><name><surname>Ebert</surname> <given-names>BL</given-names></name><name><surname>Gillette</surname> <given-names>MA</given-names></name><name><surname>Paulovich</surname> <given-names>A</given-names></name><name><surname>Pomeroy</surname> <given-names>SL</given-names></name><name><surname>Golub</surname> <given-names>TR</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name><name><surname>Mesirov</surname> <given-names>JP</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title><source>PNAS</source><volume>102</volume><fpage>15545</fpage><lpage>15550</lpage><pub-id pub-id-type="doi">10.1073/pnas.0506580102</pub-id><pub-id pub-id-type="pmid">16199517</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname> <given-names>R</given-names></name><name><surname>Nakamura</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Malignancies of natural killer (NK) cell precursor: myeloid/NK cell precursor acute leukemia and blastic NK cell lymphoma/leukemia</article-title><source>Leukemia Research</source><volume>23</volume><fpage>615</fpage><lpage>624</lpage><pub-id pub-id-type="doi">10.1016/S0145-2126(98)00194-5</pub-id><pub-id pub-id-type="pmid">10400182</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname> <given-names>Q</given-names></name><name><surname>Abdelfattah</surname> <given-names>NS</given-names></name><name><surname>Blackburn</surname> <given-names>JS</given-names></name><name><surname>Moore</surname> <given-names>JC</given-names></name><name><surname>Martinez</surname> <given-names>SA</given-names></name><name><surname>Moore</surname> <given-names>FE</given-names></name><name><surname>Lobbardi</surname> <given-names>R</given-names></name><name><surname>Tenente</surname> <given-names>IM</given-names></name><name><surname>Ignatius</surname> <given-names>MS</given-names></name><name><surname>Berman</surname> <given-names>JN</given-names></name><name><surname>Liwski</surname> <given-names>RS</given-names></name><name><surname>Houvras</surname> <given-names>Y</given-names></name><name><surname>Langenau</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Optimized cell transplantation using adult rag2 mutant zebrafish</article-title><source>Nature Methods</source><volume>11</volume><fpage>821</fpage><lpage>824</lpage><pub-id pub-id-type="doi">10.1038/nmeth.3031</pub-id><pub-id pub-id-type="pmid">25042784</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname> <given-names>Q</given-names></name><name><surname>Iyer</surname> <given-names>S</given-names></name><name><surname>Lobbardi</surname> <given-names>R</given-names></name><name><surname>Moore</surname> <given-names>JC</given-names></name><name><surname>Chen</surname> <given-names>H</given-names></name><name><surname>Lareau</surname> <given-names>C</given-names></name><name><surname>Hebert</surname> <given-names>C</given-names></name><name><surname>Shaw</surname> <given-names>ML</given-names></name><name><surname>Neftel</surname> <given-names>C</given-names></name><name><surname>Suva</surname> <given-names>ML</given-names></name><name><surname>Ceol</surname> <given-names>CJ</given-names></name><name><surname>Bernards</surname> <given-names>A</given-names></name><name><surname>Aryee</surname> <given-names>M</given-names></name><name><surname>Pinello</surname> <given-names>L</given-names></name><name><surname>Drummond</surname> <given-names>IA</given-names></name><name><surname>Langenau</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Dissecting hematopoietic and renal cell heterogeneity in adult zebrafish at single-cell resolution using RNA sequencing</article-title><source>The Journal of Experimental Medicine</source><volume>214</volume><fpage>2875</fpage><lpage>2887</lpage><pub-id pub-id-type="doi">10.1084/jem.20170976</pub-id><pub-id pub-id-type="pmid">28878000</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname> <given-names>Q</given-names></name><name><surname>Moore</surname> <given-names>JC</given-names></name><name><surname>Ignatius</surname> <given-names>MS</given-names></name><name><surname>Tenente</surname> <given-names>IM</given-names></name><name><surname>Hayes</surname> <given-names>MN</given-names></name><name><surname>Garcia</surname> <given-names>EG</given-names></name><name><surname>Torres Yordán</surname> <given-names>N</given-names></name><name><surname>Bourque</surname> <given-names>C</given-names></name><name><surname>He</surname> <given-names>S</given-names></name><name><surname>Blackburn</surname> <given-names>JS</given-names></name><name><surname>Look</surname> <given-names>AT</given-names></name><name><surname>Houvras</surname> <given-names>Y</given-names></name><name><surname>Langenau</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Imaging tumour cell heterogeneity following cell transplantation into optically clear immune-deficient zebrafish</article-title><source>Nature Communications</source><volume>7</volume><fpage>10358</fpage><pub-id pub-id-type="doi">10.1038/ncomms10358</pub-id><pub-id pub-id-type="pmid">26790525</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taubert</surname> <given-names>H</given-names></name><name><surname>Meye</surname> <given-names>A</given-names></name><name><surname>Würl</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Prognosis is correlated with p53 mutation type for soft tissue sarcoma patients</article-title><source>Cancer Research</source><volume>56</volume><fpage>4134</fpage><lpage>4136</lpage><pub-id pub-id-type="pmid">8797580</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname> <given-names>AC</given-names></name><name><surname>Shu</surname> <given-names>L</given-names></name><name><surname>Danks</surname> <given-names>MK</given-names></name><name><surname>Poquette</surname> <given-names>CA</given-names></name><name><surname>Shetty</surname> <given-names>S</given-names></name><name><surname>Thayer</surname> <given-names>MJ</given-names></name><name><surname>Houghton</surname> <given-names>PJ</given-names></name><name><surname>Harris</surname> <given-names>LC</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines</article-title><source>Medical and Pediatric Oncology</source><volume>35</volume><fpage>96</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1002/1096-911X(200008)35:2&lt;96::AID-MPO2&gt;3.0.CO;2-Z</pub-id><pub-id pub-id-type="pmid">10918230</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>TeKippe</surname> <given-names>M</given-names></name><name><surname>Harrison</surname> <given-names>DE</given-names></name><name><surname>Chen</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Expansion of hematopoietic stem cell phenotype and activity in Trp53-null mice</article-title><source>Experimental Hematology</source><volume>31</volume><fpage>521</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1016/S0301-472X(03)00072-9</pub-id><pub-id pub-id-type="pmid">12829028</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tenente</surname> <given-names>IM</given-names></name><name><surname>Hayes</surname> <given-names>MN</given-names></name><name><surname>Ignatius</surname> <given-names>MS</given-names></name><name><surname>McCarthy</surname> <given-names>K</given-names></name><name><surname>Yohe</surname> <given-names>M</given-names></name><name><surname>Sindiri</surname> <given-names>S</given-names></name><name><surname>Gryder</surname> <given-names>B</given-names></name><name><surname>Oliveira</surname> <given-names>ML</given-names></name><name><surname>Ramakrishnan</surname> <given-names>A</given-names></name><name><surname>Tang</surname> <given-names>Q</given-names></name><name><surname>Chen</surname> <given-names>EY</given-names></name><name><surname>Petur Nielsen</surname> <given-names>G</given-names></name><name><surname>Khan</surname> <given-names>J</given-names></name><name><surname>Langenau</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Myogenic regulatory transcription factors regulate growth in Rhabdomyosarcoma</article-title><source>eLife</source><volume>6</volume><elocation-id>e19214</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.19214</pub-id><pub-id pub-id-type="pmid">28080960</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>L</given-names></name><name><surname>Wang</surname> <given-names>S</given-names></name><name><surname>Li</surname> <given-names>W</given-names></name><name><surname>Wei</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>RSeQC: quality control of RNA-seq experiments</article-title><source>Bioinformatics</source><volume>28</volume><fpage>2184</fpage><lpage>2185</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts356</pub-id><pub-id pub-id-type="pmid">22743226</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yagita</surname> <given-names>M</given-names></name><name><surname>Huang</surname> <given-names>CL</given-names></name><name><surname>Umehara</surname> <given-names>H</given-names></name><name><surname>Matsuo</surname> <given-names>Y</given-names></name><name><surname>Tabata</surname> <given-names>R</given-names></name><name><surname>Miyake</surname> <given-names>M</given-names></name><name><surname>Konaka</surname> <given-names>Y</given-names></name><name><surname>Takatsuki</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation</article-title><source>Leukemia</source><volume>14</volume><fpage>922</fpage><lpage>930</lpage><pub-id pub-id-type="doi">10.1038/sj.leu.2401769</pub-id><pub-id pub-id-type="pmid">10803526</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname> <given-names>Z</given-names></name><name><surname>Zuber</surname> <given-names>J</given-names></name><name><surname>Diaz-Flores</surname> <given-names>E</given-names></name><name><surname>Lintault</surname> <given-names>L</given-names></name><name><surname>Kogan</surname> <given-names>SC</given-names></name><name><surname>Shannon</surname> <given-names>K</given-names></name><name><surname>Lowe</surname> <given-names>SW</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal</article-title><source>Genes &amp; Development</source><volume>24</volume><fpage>1389</fpage><lpage>1402</lpage><pub-id pub-id-type="doi">10.1101/gad.1940710</pub-id><pub-id pub-id-type="pmid">20595231</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.37202.031</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>White</surname><given-names>Richard M</given-names></name><role>Reviewing Editor</role><aff><institution>Memorial Sloan Kettering Cancer Center</institution><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Houvras</surname><given-names>Yariv</given-names> </name><role>Reviewer</role><aff><institution>Weill Cornell Medical College</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.</p></boxed-text><p>Thank you for submitting your article &quot;<italic>tp53</italic> deficiency causes a wide tumor spectrum and elevates embryonal rhabdomyosarcoma metastasis in zebrafish&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Marianne Bronner as the Senior Editor. The following individual involved in review of your submission has agreed to reveal his identity: Yariv Houvras (Reviewer #2).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>Summary:</p><p>In this work, the authors have constructed a new <italic>tp53</italic> deficient zebrafish strain in a CG1 syngeneic background. This will enable the study of tumors without the need for immunocompromised status. They then go on to show that this loss correlates with invasive and metastatic potential. This work further opens up the field for delineating how this important tumor suppressor can contribute to a variety of tumor progression models.</p><p>Essential revisions:</p><p>The major experiments asked for by the reviewers can be grouped into the following two categories, one focused on the point vs. del mutant, and the other on the methods used for gene expression analysis:</p><p>1) Comparison of the deletion mutant to the point mutant:a) Since <italic>Tp53</italic> mutation in zebrafish only induces MPNST, does it promote RMS metastasis or not? This would be very interesting to know in order to further understand how <italic>Tp53</italic> contributes to RMS progression.</p><p>b) Another interesting question is: Are MPNST gene expression profiles derived from <italic>Tp53</italic> mutant fish similar to those of MPNST from <italic>Tp53<sup>del/del</sup></italic> fish? This may help us to understand how <italic>P53</italic> mutation and loss-of-function behave in regulating gene transcription.</p><p>c) The lack of change in tumor propagating stem cells is interesting in the <italic>tp53<sup>del/del</sup></italic> ERMS. Is this also the case for <italic>tp53</italic>(point mutant) allele ERMS models? If not, this might help bolster the case that <italic>tp53<sup>del/del</sup></italic> may be a valuable allele.</p><p>d) The increased metastasis observed in the <italic>tp53<sup>del/del</sup></italic> ERMS model may be due to the increase number of spontaneous tumors in <italic>tp53<sup>del/del</sup></italic>. This doesn't mean that there isn't an increase in metastasis, but that the result might be conflated with the fact that the animal may be unhealthy due to already existing tumors. Have the authors looked at whether the GFP+ positive metastasized fish also have non GFP+ tumors?</p><p>2) The gene expression analyses: a) Assigning NK cell of origin to the leukemias. The authors have used their prior gene expression data from single cell studies and overlap with known markers in human NK cells to make this claim. Are there human gene expression data on NK cell leukemia that further supports this claim? Can they exclude the possibility that the leukemic blasts they identify are myeloid in origin but lack differentiated markers and represent a more primitive myeloid state. Can they examine myeloid markers on cytospin preparations to further evaluate this possibility? The authors' claim would be strengthened if they are able to relate the gene expression to published NK cell gene expression signatures, if possible. The authors should consider modifying the claim that they can identify the lineage with absolute certainty based on the available data.</p><p>b) The gene expression studies are elegant, yet I would like to see more detail included in the manuscript with regard to certain details. What controls did the authors use for each tissue type? The conclusion sentence (subsection “Gene expression analysis of <italic>tp53<sup>del/del</sup></italic>tumors arising in transplant recipient fish”, first paragraph) depends on understanding what the comparison is.</p><p>c) The GSEA results for <italic>tp53<sup>del/del</sup></italic> tumors were not entirely surprising given the tissue origin (i.e. I would expect that the angiosarcoma would have enrichment of vascular genes). The data set would hold a lot more value if the tumor profile for each of the tumors were compared to &quot;normal&quot; tissue of the same type (i.e. leukemia tumor cells compared to normal fish blood cells), rather than whole syngeneic fish. Additionally, have the GO sets been compared to GO sets in human disease, and what is the overlap?</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.37202.032</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>The major experiments asked for by the reviewers can be grouped into the following two categories, one focused on the point vs. del mutant, and the other on the methods used for gene expression analysis:</p><p>1) Comparison of the deletion mutant to the point mutant:a) Since Tp53 mutation in zebrafish only induces MPNST, does it promote RMS metastasis or not? This would be very interesting to know in order to further understand how Tp53 contributes to RMS progression.</p></disp-quote><p>We analyzed the small cohort of <italic>tp53</italic> point mutant zebrafish that we maintain in the lab and did not have fish in the correct age class to find MPNSTs (they develop around 14 months of age). Moreover, the point mutant line is not in the CG1 strain background, confounding direct comparison to <italic>tp53<sup>del/del</sup></italic>tumors. Although we agree these experiments would be interesting, potential impacts of strain differences and lack of animals prevented us from being able to complete these experiments during the allotted 3 month resubmission period.</p><disp-quote content-type="editor-comment"><p>b) Another interesting question is: Are MPNST gene expression profiles derived from Tp53 mutant fish similar to those of MPNST from Tp53<sup>del/del</sup> fish? This may help us to understand how P53 mutation and loss-of-function behave in regulating gene transcription.</p></disp-quote><p>To address this question, we reached out to members of the zebrafish cancer community and have obtained RNAseq data from four <italic>tp53<sup>M214K/M214K</sup></italic> MPNSTs and compared expression signatures to <italic>tp53<sup>del/del</sup> </italic>MPNSTs. We identified significant overlap between <italic>p53<sup>M214K/M214K</sup></italic> and <italic>p53<sup>del/del</sup></italic> MPNST (<xref ref-type="fig" rid="respfig1">Author response image 1</xref>, p=4e-321 for up-regulated genes and p=5e-182 for downregulated genes; one-sided Fisher’s exact test), suggesting functional commonalities between the different alleles. This is expected given the loss-of-function phenotypes previously reported for <italic>tp53<sup>M214K/M214K</sup> </italic>(Berghmans et al., 2005). We have added these data to the revised manuscript and included gene lists for these comparisons in Supplementary file 5.</p><fig id="respfig1"><label>Author response image 1.</label><caption><title>Venn diagram depicting overlap between up-regulated and down-regulated genes when comparing homozygous mutant <italic><sup>tp53M214K/M214K</sup></italic>and <italic>tp53<sup>del/del</sup></italic>MPNST to whole adult zebrafish.</title></caption><graphic mime-subtype="png" mimetype="image" xlink:href="elife-37202-resp-fig1-v1"/></fig><disp-quote content-type="editor-comment"><p>c) The lack of change in tumor propagating stem cells is interesting in the tp53<sup>del/del</sup> ERMS. Is this also the case for tp53(point mutant) allele ERMS models? If not, this might help bolster the case that tp53<sup>del/del</sup> may be a valuable allele.</p></disp-quote><p>Sadly, the <italic>tp53</italic> point mutations have not been generated in the syngeneic CG1 strain zebrafish, obviating our ability to complete these interesting analysis. Syngeneic models are required to accurately assess stem cell frequency following limiting dilution cell transplantation (Smith et al., 2010; Blackburn et al., 2012; Ignatius et al., 2012; Blackburn et al., 2014; Ignatius et al., 2017; Hayes et al., 2018; Garcia et al., 2018). Future studies, which are currently beyond the scope of this work, could generate patient-specific point mutations in syngeneic lines and assess for effects on ERMS stem cell frequency.</p><disp-quote content-type="editor-comment"><p>d) The increased metastasis observed in the tp53<sup>del/del</sup> ERMS model may be due to the increase number of spontaneous tumors in tp53<sup>del/del</sup>. This doesn't mean that there isn't an increase in metastasis, but that the result might be conflated with the fact that the animal may be unhealthy due to already existing tumors. Have the authors looked at whether the GFP+ positive metastasized fish also have non GFP+ tumors?</p></disp-quote><p>We are sorry that our initial presentation of our experimental design was confusing. Here, GFP-labeled <italic>kRAS<sup>G12D</sup></italic>-induced ERMS were generated in CG1 <italic>tp53<sup>wt/wt</sup> </italic>and <italic>tp53<sup>del/del</sup></italic>zebrafish. Primary tumor cells were then harvested from both genotypes and transplanted into wild-type, non-GFP expressing CG1 recipient animals. These recipient fish do not transgenically express GFP endogenously, and thus any GFP mass must be derived from engrafted cells.</p><p>To rule out the possibility of other spontaneous tumors arising in CG1 syngeneic transplant fish, we looked at H&amp;E stained sections of recipient animals engrafted with <italic>tp53<sup>del/del</sup> </italic>ERMS and confirmed the presence of only ERMS (n=19). A subset of animals were also assessed by anti-GFP immunostaining on section, confirming that identified tumors were only derived from GFP+ ERMS engrafted cells and did not arise from recipient fish tissues.</p><disp-quote content-type="editor-comment"><p>2) The gene expression analyses:a) Assigning NK cell of origin to the leukemias. The authors have used their prior gene expression data from single cell studies and overlap with known markers in human NK cells to make this claim. Are there human gene expression data on NK cell leukemia that further supports this claim? The authors' claim would be strengthened if they are able to relate the gene expression to published NK cell gene expression signatures, if possible. The authors should consider modifying the claim that they can identify the lineage with absolute certainty based on the available data.</p></disp-quote><p>Unfortunately, expression data sets for human ANKL tumors are not currently available, likely due to the rarity of these tumors.</p><p>Yet to directly address this important reviewer comment, we have now completed additional analysis to support the similarity of zebrafish NK cell leukemias with normal NK and NK-like cells from zebrafish. For example, we have expanded the original analysis to show individual gene expression data in Figure 3D (see Figure 3—figure supplement 1D) and updated gene expression analysis in Figure 3E, showing a heat map for expression of well-known NK cell marker genes across tumor types and individuals.</p><p>We have also now completed additional experiments to support the assignment of these tumors to the NK cell lineage. Specifically, we identified the top 200 most differentially regulated genes in leukemias compared to all other tumor types and assessed if these genes were differentially expressed within defined blood cell lineages from the zebrafish. We specifically assessed expression using the SMARTseq single cell gene expression dataset from Tang et al., 2017 which included HSC/progenitors isolated as <italic>cd41:</italic>GFP<sup>low</sup> cells from <italic>tg(cd41:GFP)</italic> transgenic zebrafish, T cells from <italic>tg(lck:GFP)</italic> transgenic zebrafish, NK cells from <italic>rag1-/-, tg(lck:GFP)</italic> transgenic zebrafish, myeloid cells from <italic>tg(mpx:EGFP)</italic> transgenic zebrafish, B cells from marrow-derived <italic>tg(rag2:GFP)</italic> transgenic zebrafish, and HSCs from <italic>tg(runx1<sup>+23</sup>:GFP)</italic> transgenic zebrafish. Significant enrichment was only observed in NK cells (Figure 3—figure supplement 1E, p=0.015, one-sided binomial test), supporting a NK cell origin of <italic>tp53<sup>del/del</sup></italic> leukemias.</p><p>Finally<italic>, tp53<sup>del/del</sup></italic> NK cell-like leukemias also expressed well-known genes commonly associated with human NK cells, including <italic>il2ga</italic> and <italic>b, jak3, perforins 2, 7,</italic> and <italic>8</italic>, and these genes were highly up-regulated when compared to all other tumor types in our analysis (Figure 3E).</p><disp-quote content-type="editor-comment"><p>Can they exclude the possibility that the leukemic blasts they identify are myeloid in origin but lack differentiated markers and represent a more primitive myeloid state. Can they examine myeloid markers on cytospin preparations to further evaluate this possibility?</p></disp-quote><p>To address this reviewer comment, we have used our previously published single cell expression data (Tang et al., 2017) to show significant enrichment of NK cell gene expression in <italic>tp53<sup>del/del</sup> </italic>leukemias and not other cell lineages (see above and Figure 3 and Figure 3—figure supplement 1).</p><p>We have also now included analysis of myeloid genes and confirm that they are not differentially upregulated in leukemias when compared with whole fish (see Figure 3—figure supplement 1D and Supplementary file 7).</p><disp-quote content-type="editor-comment"><p>b) The gene expression studies are elegant, yet I would like to see more detail included in the manuscript with regard to certain details. What controls did the authors use for each tissue type? The conclusion sentence (subsection “Gene expression analysis of tp53<sup>del/del</sup> tumors arising in transplant recipient fish”, first paragraph) depends on understanding what the comparison is.</p></disp-quote><p>We are sorry for this confusion and have amended the revised manuscript to clarify these comparisons throughout.</p><disp-quote content-type="editor-comment"><p>c) The GSEA results for tp53<sup>del/del</sup> tumors were not entirely surprising given the tissue origin (i.e. I would expect that the angiosarcoma would have enrichment of vascular genes). The data set would hold a lot more value if the tumor profile for each of the tumors were compared to &quot;normal&quot; tissue of the same type (i.e. leukemia tumor cells compared to normal fish blood cells), rather than whole syngeneic fish. Additionally, have the GO sets been compared to GO sets in human disease, and what is the overlap?</p></disp-quote><p>To validate our assigned tumor designations, we have now assessed if zebrafish tumors express tumor-specific gene signatures identified in human angiosarcoma (Andersen et al., 2013), MPNST (Kolberg et al., 2015) and ERMS (experimentally determined using GEO:GSE108022) (Supplementary file 4). Using Gene set enrichment analysis (GSEA), we report significant enrichment of signatures associated with human angiosarcoma (FDR q-value = 0.001, Figure 3—figure supplement 1A), MPNST (FDR q-value = 0.00433526, Figure 3—figure supplement 1B), and ERMS (FDR q-value = 0, Figure 3—figure supplement 1C) only in the corresponding <italic>tp53<sup>del/del</sup></italic> zebrafish tumors (Supplementary file 4). Taken together, these data reveal conserved gene expression programs associated with both the predicted cells of origin and corresponding human cancer counterpart.</p></body></sub-article></article>